{
 "_what": "Grey Peptides pipeline tracker (Q947): peptide and peptide-based drugs approved since 2025, in clinical development, announced by their company with no registered trial (phase 'announced', Q956), published pre-clinically, or rumoured by a named news outlet (phase 'rumoured'), one row per molecule (or per molecule-indication where a known drug is being tested for a new use). Every claim names its source key; every NCT id has a cached registry record in _ops/pipeline_ct/. Rendered by _ops/pipeline_page.py to /pipeline/; gated by pipeline_tracker_current (a row older than 45 days fails).",
 "phases": [
  "approved-2025-26",
  "filed",
  "phase 3",
  "phase 2",
  "phase 1",
  "announced",
  "preclinical",
  "rumoured"
 ],
 "areas": {
  "obesity-diabetes": "Obesity and diabetes",
  "cardiometabolic": "Cardiometabolic and liver",
  "rare-disease": "Rare disease",
  "endocrine": "Endocrine",
  "dermatology": "Dermatology",
  "gi": "Gut and liver",
  "oncology": "Oncology and radioligands",
  "antimicrobial": "Antimicrobials"
 },
 "freshness_days": 45,
 "rows": [
  {
   "id": "icotrokinra",
   "name": "Icotrokinra",
   "aliases": [
    "Icotyde",
    "JNJ-77242113",
    "JNJ-2113"
   ],
   "sponsor": "Johnson & Johnson (Janssen); discovered with Protagonist Therapeutics",
   "target": "Interleukin-23 receptor",
   "mechanism": "Binds the IL-23 receptor and blocks IL-23 signalling",
   "areas": [
    "dermatology",
    "gi"
   ],
   "indications": [
    "Plaque psoriasis (approved)",
    "Psoriatic arthritis",
    "Ulcerative colitis",
    "Crohn's disease"
   ],
   "phase": "approved-2025-26",
   "phase_note": "FDA approval March 17, 2026 for moderate-to-severe plaque psoriasis; phase 3 in psoriatic arthritis and ulcerative colitis, phase 2b/3 in Crohn's disease",
   "phase_sources": [
    "fda",
    "uc"
   ],
   "ncts": [
    "NCT06095115",
    "NCT06807424",
    "NCT07196748",
    "NCT07196722"
   ],
   "last_readout": {
    "date": "2025-11-06",
    "result": "ICONIC-LEAD: 65% clear or almost clear skin at week 16 against 8% on placebo (684 adults and adolescents)",
    "source": "lead"
   },
   "next_milestone": {
    "what": "Primary completion of the ICONIC-PsA 2 phase 3 trial in psoriatic arthritis",
    "expected": "2027-02-10",
    "source": "psa"
   },
   "plain": "Icotrokinra is a small ring-shaped peptide taken as a daily pill. It blocks the receptor for a signal called IL-23 that keeps psoriasis flaring, so the skin can clear.",
   "scientific": "Icotrokinra is a targeted oral peptide that selectively binds the interleukin-23 receptor, interrupting IL-23 signalling. In the phase 3 ICONIC-LEAD trial it met both co-primary endpoints (IGA 0/1 and PASI 90 at week 16) against placebo, and the share of participants with any adverse event was the same in both groups. Phase 3 trials in psoriatic arthritis and ulcerative colitis and a phase 2b/3 in Crohn's disease test it beyond the skin.",
   "entry": "icotrokinra",
   "sources": {
    "fda": {
     "kind": "regulator",
     "label": "FDA, Novel Drug Approvals for 2026 (Icotyde, March 17, 2026)",
     "url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026",
     "read": "2026-10-28",
     "date": "2026-03-17"
    },
    "lead": {
     "kind": "paper",
     "label": "Bissonnette R, et al. Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents. N Engl J Med 2025;393:1784-1795 (ICONIC-LEAD)",
     "pmid": "41191940",
     "url": "https://pubmed.ncbi.nlm.nih.gov/41191940/",
     "read": "2026-10-28"
    },
    "psa": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06807424 (ICONIC-PsA 2)",
     "url": "https://clinicaltrials.gov/study/NCT06807424",
     "nct": "NCT06807424",
     "read": "2026-10-28"
    },
    "uc": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07196748 (ICONIC-UC)",
     "url": "https://clinicaltrials.gov/study/NCT07196748",
     "nct": "NCT07196748",
     "read": "2026-10-28"
    },
    "lead_reg": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06095115 (ICONIC-LEAD)",
     "url": "https://clinicaltrials.gov/study/NCT06095115",
     "nct": "NCT06095115",
     "read": "2026-10-28"
    },
    "cd": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07196722 (ICONIC-CD)",
     "url": "https://clinicaltrials.gov/study/NCT07196722",
     "nct": "NCT07196722",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-03-17",
    "what": "FDA approved as Icotyde for plaque psoriasis",
    "source": "fda"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "lead",
    "psa",
    "uc",
    "cd"
   ],
   "class": "Oral cyclic peptide"
  },
  {
   "id": "enlicitide",
   "name": "Enlicitide decanoate",
   "aliases": [
    "Lipfendra",
    "MK-0616"
   ],
   "sponsor": "Merck (MSD)",
   "target": "PCSK9",
   "mechanism": "Binds PCSK9 so more LDL receptors stay on liver cells",
   "areas": [
    "cardiometabolic"
   ],
   "indications": [
    "High LDL cholesterol, including heterozygous familial hypercholesterolaemia (approved)",
    "Cardiovascular outcomes (in trial)"
   ],
   "phase": "approved-2025-26",
   "phase_note": "FDA approval July 15, 2026; cardiovascular outcomes trial running",
   "phase_sources": [
    "fda"
   ],
   "ncts": [
    "NCT05952856",
    "NCT05952869",
    "NCT06450366",
    "NCT06008756"
   ],
   "last_readout": {
    "date": "2026-01-13",
    "result": "Phase 3 in heterozygous familial hypercholesterolaemia: LDL cholesterol fell 58.2% at week 24 against a 2.6% rise on placebo",
    "source": "hefh"
   },
   "next_milestone": {
    "what": "Primary completion of CORALreef Outcomes, the 14,550-person cardiovascular outcomes trial",
    "expected": "2029-11-29",
    "source": "cvot"
   },
   "plain": "Enlicitide is a cholesterol pill made from a ring-shaped peptide. It blocks a protein called PCSK9, which lets the liver pull more 'bad' LDL cholesterol out of the blood.",
   "scientific": "Enlicitide decanoate is an oral macrocyclic peptide inhibitor of proprotein convertase subtilisin/kexin type 9, the protein that sends LDL receptors for degradation. In phase 3 trials on top of statins it lowered LDL-C, apolipoprotein B, non-HDL cholesterol and lipoprotein(a) against placebo, and in CORALreef AddOn it lowered LDL-C more than ezetimibe, bempedoic acid or both. Whether it reduces heart attacks and strokes is the question the CORALreef Outcomes trial is built to answer.",
   "entry": "enlicitide",
   "sources": {
    "fda": {
     "kind": "regulator",
     "label": "FDA, Novel Drug Approvals for 2026 (Lipfendra, July 15, 2026)",
     "url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026",
     "read": "2026-10-28",
     "date": "2026-07-15"
    },
    "hefh": {
     "kind": "paper",
     "label": "Ballantyne CM, et al. Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia. JAMA 2026",
     "pmid": "41206969",
     "url": "https://pubmed.ncbi.nlm.nih.gov/41206969/",
     "read": "2026-10-28"
    },
    "addon": {
     "kind": "paper",
     "label": "Catapano AL, et al. Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial. J Am Coll Cardiol 2026",
     "pmid": "42017875",
     "url": "https://pubmed.ncbi.nlm.nih.gov/42017875/",
     "read": "2026-10-28"
    },
    "cvot": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06008756 (Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes)",
     "url": "https://clinicaltrials.gov/study/NCT06008756",
     "nct": "NCT06008756",
     "read": "2026-10-28"
    },
    "lipids": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT05952856 (A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids)",
     "url": "https://clinicaltrials.gov/study/NCT05952856",
     "nct": "NCT05952856",
     "read": "2026-10-28"
    },
    "hefh_reg": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT05952869 (A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH))",
     "url": "https://clinicaltrials.gov/study/NCT05952869",
     "nct": "NCT05952869",
     "read": "2026-10-28"
    },
    "addon_reg": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06450366 (A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn))",
     "url": "https://clinicaltrials.gov/study/NCT06450366",
     "nct": "NCT06450366",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-07-15",
    "what": "FDA approved as Lipfendra",
    "source": "fda"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "hefh",
    "addon",
    "cvot"
   ],
   "class": "Oral macrocyclic peptide"
  },
  {
   "id": "navepegritide",
   "name": "Navepegritide",
   "aliases": [
    "Yuviwel",
    "TransCon CNP"
   ],
   "sponsor": "Ascendis Pharma",
   "target": "Natriuretic peptide receptor B (NPR-B)",
   "mechanism": "Releases CNP slowly; CNP counteracts the overactive FGFR3 brake on growth plates",
   "areas": [
    "rare-disease",
    "endocrine"
   ],
   "indications": [
    "Achondroplasia in children (approved in the US, accelerated; recommended in the EU)"
   ],
   "phase": "approved-2025-26",
   "phase_note": "FDA accelerated approval February 27, 2026; EMA's CHMP recommended EU authorisation on October 16, 2026 (European Commission decision pending); infant and adolescent trials continue",
   "phase_sources": [
    "fda",
    "ema_chmp"
   ],
   "ncts": [
    "NCT05598320",
    "NCT06079398",
    "NCT06433557"
   ],
   "last_readout": {
    "date": "2026-01-01",
    "result": "ApproaCH: annualised growth velocity 1.49 cm a year higher than placebo at week 52 (84 children)",
    "source": "approach"
   },
   "next_milestone": {
    "what": "Primary completion of the placebo-controlled trial in infants under 2 years",
    "expected": "2027-12",
    "source": "infant"
   },
   "plain": "Children with achondroplasia have a gene change that puts the brakes on bone growth. Navepegritide is a once-a-week injection that slowly releases a natural growth signal called CNP, which works against that brake. Children on it grew faster than children on placebo.",
   "scientific": "Navepegritide is a prodrug of C-type natriuretic peptide built for once-weekly dosing. Achondroplasia is caused by a gain-of-function variant in fibroblast growth factor receptor 3, which restrains growth-plate chondrocytes; CNP signalling opposes that restraint. In ApproaCH, a phase 2b randomised trial, annualised growth velocity at week 52 was higher than on placebo, with improvements in some leg-alignment measures and no treatment-related serious adverse events. The approval is accelerated, so continued approval depends on confirmatory evidence.",
   "entry": "navepegritide",
   "sources": {
    "fda": {
     "kind": "regulator",
     "label": "FDA, Novel Drug Approvals for 2026 (Yuviwel, February 27, 2026)",
     "url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026",
     "read": "2026-10-28",
     "date": "2026-02-27"
    },
    "approach": {
     "kind": "paper",
     "label": "Savarirayan R, et al. Once-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical Trial. JAMA Pediatr 2026",
     "pmid": "41247754",
     "url": "https://pubmed.ncbi.nlm.nih.gov/41247754/",
     "read": "2026-10-28"
    },
    "infant": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06079398 (A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia)",
     "url": "https://clinicaltrials.gov/study/NCT06079398",
     "nct": "NCT06079398",
     "read": "2026-10-28"
    },
    "approach_reg": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT05598320 (ApproaCH)",
     "url": "https://clinicaltrials.gov/study/NCT05598320",
     "nct": "NCT05598320",
     "read": "2026-10-28"
    },
    "coach": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06433557 (COACH)",
     "url": "https://clinicaltrials.gov/study/NCT06433557",
     "nct": "NCT06433557",
     "read": "2026-10-28"
    },
    "ema_chmp": {
     "kind": "regulator",
     "label": "EMA: Meeting highlights from the CHMP, 12-15 October 2026 (Yuviwel positive opinion)",
     "url": "https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2026",
     "date": "2026-10-16",
     "read": "2026-11-03"
    }
   },
   "changed": {
    "date": "2026-10-16",
    "what": "CHMP positive opinion for Yuviwel in the EU",
    "source": "ema_chmp"
   },
   "last_checked": "2026-11-03",
   "explainer_sources": [
    "approach",
    "fda"
   ],
   "class": "Long-acting prodrug of C-type natriuretic peptide"
  },
  {
   "id": "bulevirtide",
   "name": "Bulevirtide",
   "aliases": [
    "Hepcludex",
    "Myrcludex B"
   ],
   "sponsor": "Gilead Sciences",
   "target": "NTCP (sodium taurocholate co-transporting polypeptide)",
   "mechanism": "Occupies the bile-acid transporter that hepatitis B and D viruses use to enter liver cells",
   "areas": [
    "rare-disease",
    "gi"
   ],
   "indications": [
    "Chronic hepatitis D (approved in the US May 2026)"
   ],
   "phase": "approved-2025-26",
   "phase_note": "US approval May 22, 2026 (already authorised in the EU)",
   "phase_sources": [
    "label"
   ],
   "ncts": [
    "NCT03852719",
    "NCT07142811"
   ],
   "last_readout": {
    "date": "2026-04-09",
    "result": "MYR301 final results: virologic response in 73% to 92% of groups at end of 144 weeks; responses fell after stopping, though some patients stayed undetectable",
    "source": "myr301"
   },
   "next_milestone": {
    "what": "Primary completion of a phase 2 comparing Vir's tobevibart plus elebsiran with bulevirtide",
    "expected": "2026-11",
    "source": "vir"
   },
   "plain": "Hepatitis D is a liver virus that needs a doorway on liver cells to get in. Bulevirtide is a daily injection that blocks that doorway, so the virus cannot infect new cells.",
   "scientific": "Bulevirtide is a lipopeptide that binds the sodium taurocholate co-transporting polypeptide (NTCP), the hepatocyte bile-acid transporter that hepatitis B and D viruses use as their entry receptor, and so blocks viral entry. In the phase 3 MYR301 trial virologic and biochemical responses were maintained over 144 weeks of monotherapy. Responses fell after treatment stopped, although some patients who were undetectable at the end of treatment stayed undetectable.",
   "entry": "bulevirtide",
   "sources": {
    "label": {
     "kind": "regulator",
     "label": "Hepcludex (bulevirtide) US prescribing information, DailyMed set 12391cc2, version 1, effective May 22, 2026",
     "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12391cc2-38c2-4cf5-86d3-2be9370127fc",
     "read": "2026-10-28",
     "date": "2026-05-22"
    },
    "myr301": {
     "kind": "paper",
     "label": "Wedemeyer H, et al. 144 Weeks of bulevirtide monotherapy for chronic hepatitis D: final and post-treatment results from a phase III randomized trial. J Hepatol 2026",
     "pmid": "41966308",
     "url": "https://pubmed.ncbi.nlm.nih.gov/41966308/",
     "read": "2026-10-28"
    },
    "vir": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07142811 (A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection)",
     "url": "https://clinicaltrials.gov/study/NCT07142811",
     "nct": "NCT07142811",
     "read": "2026-10-28"
    },
    "myr_reg": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT03852719 (Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD))",
     "url": "https://clinicaltrials.gov/study/NCT03852719",
     "nct": "NCT03852719",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-05-22",
    "what": "US approval as Hepcludex",
    "source": "label"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "label",
    "myr301"
   ],
   "class": "Lipopeptide entry inhibitor"
  },
  {
   "id": "rusfertide",
   "name": "Rusfertide",
   "aliases": [
    "Mimrylo",
    "PTG-300",
    "TAK-121"
   ],
   "sponsor": "Takeda (developed by Protagonist Therapeutics)",
   "target": "Ferroportin",
   "mechanism": "Mimics hepcidin, lowering the iron available for red-cell production",
   "areas": [
    "rare-disease"
   ],
   "indications": [
    "Erythrocytosis in polycythaemia vera (approved)"
   ],
   "phase": "approved-2025-26",
   "phase_note": "FDA approval August 28, 2026; Japanese and Chinese studies registered",
   "phase_sources": [
    "fda"
   ],
   "ncts": [
    "NCT05210790",
    "NCT06033586",
    "NCT07648030"
   ],
   "last_readout": {
    "date": "2026-10-13",
    "result": "VERIFY published (J Clin Oncol): 77% of 147 patients on rusfertide had a clinical response between weeks 20 and 32, against 33% of 146 on placebo",
    "source": "verify_jco"
   },
   "next_milestone": {
    "what": "Primary completion of the phase 2 study in Japanese adults",
    "expected": "2027-10-28",
    "source": "japan"
   },
   "plain": "In polycythaemia vera the bone marrow makes far too many red blood cells, and many patients need blood taken off regularly. Rusfertide copies a natural hormone, hepcidin, that locks iron away, so the marrow cannot make as many red cells. In its main trial fewer people needed blood removed.",
   "scientific": "Rusfertide is a hepcidin mimetic: like hepcidin, it acts on ferroportin, the cellular iron exporter, restricting the iron supply to red-cell production. In the phase 3 VERIFY trial fewer patients met criteria for phlebotomy than on placebo. Reviews note that the evidence rests on haematocrit and phlebotomy endpoints, and whether this lowers the risk of blood clots has not been shown.",
   "entry": "rusfertide",
   "sources": {
    "fda": {
     "kind": "regulator",
     "label": "FDA press announcement: FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder (August 28, 2026)",
     "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder",
     "read": "2026-10-28",
     "date": "2026-08-28"
    },
    "verify": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT05210790 (VERIFY)",
     "url": "https://clinicaltrials.gov/study/NCT05210790",
     "nct": "NCT05210790",
     "read": "2026-10-28"
    },
    "thrive": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06033586 (THRIVE)",
     "url": "https://clinicaltrials.gov/study/NCT06033586",
     "nct": "NCT06033586",
     "read": "2026-10-28"
    },
    "japan": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07648030 (A Study of Rusfertide in Japanese Adults With Polycythemia Vera)",
     "url": "https://clinicaltrials.gov/study/NCT07648030",
     "nct": "NCT07648030",
     "read": "2026-10-28"
    },
    "review": {
     "kind": "paper",
     "label": "Costa A, et al. Targeting the hepcidin-ferroportin axis in polycythemia vera: a complementary approach to clone-directed therapies. Blood Rev 2026",
     "pmid": "42660705",
     "url": "https://pubmed.ncbi.nlm.nih.gov/42660705/",
     "read": "2026-10-28"
    },
    "verify_jco": {
     "kind": "paper",
     "label": "Kuykendall AT, et al. VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy. J Clin Oncol 2026",
     "pmid": "42868322",
     "url": "https://pubmed.ncbi.nlm.nih.gov/42868322/",
     "read": "2026-11-03"
    }
   },
   "changed": {
    "date": "2026-10-13",
    "what": "VERIFY phase 3 published in the Journal of Clinical Oncology",
    "source": "verify_jco"
   },
   "last_checked": "2026-11-03",
   "explainer_sources": [
    "fda",
    "review",
    "verify_jco"
   ],
   "class": "Hepcidin mimetic peptide"
  },
  {
   "id": "insulin-icodec",
   "name": "Insulin icodec",
   "aliases": [
    "Awiqli"
   ],
   "sponsor": "Novo Nordisk",
   "target": "Insulin receptor",
   "mechanism": "Binds albumin in the blood and releases insulin activity slowly over a week",
   "areas": [
    "obesity-diabetes"
   ],
   "indications": [
    "Type 2 diabetes (approved); not approved for type 1"
   ],
   "phase": "approved-2025-26",
   "phase_note": "FDA approval March 26, 2026 for adults with type 2 diabetes",
   "phase_sources": [
    "fda"
   ],
   "ncts": [
    "NCT04460885",
    "NCT07076199"
   ],
   "last_readout": {
    "date": "2026-03-26",
    "result": "FDA approval for adults with type 2 diabetes; type 1 diabetes not included",
    "source": "fda"
   },
   "next_milestone": {
    "what": "Primary completion of ONWARDS 11, a further phase 3 trial",
    "expected": "2027-01-25",
    "source": "onwards11"
   },
   "plain": "Insulin icodec is a long-acting insulin injected once a week instead of once a day. It is approved for adults with type 2 diabetes only.",
   "scientific": "Insulin icodec is a basal insulin analogue designed for once-weekly injection, tested against daily basal insulins in the ONWARDS phase 3 programme. FDA approved it in March 2026 for adults with type 2 diabetes; it is not approved for type 1 diabetes. Further phase 3 trials, such as ONWARDS 11, are still running.",
   "entry": "insulin-icodec",
   "sources": {
    "fda": {
     "kind": "regulator",
     "label": "FDA, Novel Drug Approvals for 2026 (Awiqli, March 26, 2026)",
     "url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026",
     "read": "2026-10-28",
     "date": "2026-03-26"
    },
    "onwards1": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT04460885 (ONWARDS 1)",
     "url": "https://clinicaltrials.gov/study/NCT04460885",
     "nct": "NCT04460885",
     "read": "2026-10-28"
    },
    "onwards11": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07076199 (ONWARDS 11)",
     "url": "https://clinicaltrials.gov/study/NCT07076199",
     "nct": "NCT07076199",
     "read": "2026-10-28"
    },
    "medlet": {
     "kind": "paper",
     "label": "Once-weekly insulin icodec (Awiqli) for type 2 diabetes. Med Lett Drugs Ther 2026",
     "pmid": "42752391",
     "url": "https://pubmed.ncbi.nlm.nih.gov/42752391/",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-03-26",
    "what": "FDA approved as Awiqli for type 2 diabetes",
    "source": "fda"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "fda",
    "medlet",
    "onwards1",
    "onwards11"
   ],
   "class": "Once-weekly basal insulin analogue"
  },
  {
   "id": "insulin-efsitora",
   "name": "Insulin efsitora alfa",
   "aliases": [
    "Onswik",
    "LY3209590",
    "basal insulin Fc"
   ],
   "sponsor": "Eli Lilly",
   "target": "Insulin receptor",
   "mechanism": "An insulin variant fused to an antibody Fc fragment, which slows its clearance to about a week",
   "areas": [
    "obesity-diabetes"
   ],
   "indications": [
    "Type 2 diabetes (approved); not approved for type 1"
   ],
   "phase": "approved-2025-26",
   "phase_note": "FDA approval September 23, 2026; the second weekly insulin in the US",
   "phase_sources": [
    "fda"
   ],
   "ncts": [
    "NCT05362058",
    "NCT05462756"
   ],
   "last_readout": {
    "date": "2026-09-23",
    "result": "FDA approval for adults with type 2 diabetes on the QWINT phase 3 programme",
    "source": "fda"
   },
   "next_milestone": {
    "what": "No further registered trial with a future completion date was found in the registry search",
    "expected": null,
    "source": "q"
   },
   "plain": "Insulin efsitora is another once-a-week insulin injection. It is approved for adults with type 2 diabetes.",
   "scientific": "Insulin efsitora alfa, studied as basal insulin Fc, is a once-weekly basal insulin. A meta-analysis of five randomised trials against daily degludec found similar overall glucose control and time in range, but more time in mild hypoglycaemia and higher rates of clinically significant and severe hypoglycaemia. FDA approved it in September 2026 for adults with type 2 diabetes; it is not approved for type 1.",
   "entry": "insulin-efsitora",
   "sources": {
    "fda": {
     "kind": "regulator",
     "label": "FDA, Novel Drug Approvals for 2026 (Onswik, September 23, 2026)",
     "url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026",
     "read": "2026-10-28",
     "date": "2026-09-23"
    },
    "qwint2": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT05362058 (QWINT-2)",
     "url": "https://clinicaltrials.gov/study/NCT05362058",
     "nct": "NCT05362058",
     "read": "2026-10-28"
    },
    "qwint4": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT05462756 (QWINT-4)",
     "url": "https://clinicaltrials.gov/study/NCT05462756",
     "nct": "NCT05462756",
     "read": "2026-10-28"
    },
    "q": {
     "kind": "registry",
     "label": "ClinicalTrials.gov search for insulin efsitora (read October 28, 2026): five phase 3 studies, all completed",
     "url": "https://clinicaltrials.gov/search?intr=insulin%20efsitora",
     "read": "2026-10-28"
    },
    "bif": {
     "kind": "paper",
     "label": "Abunada S, et al. Continuous Glucose Monitoring and Hypoglycaemia Metrics With Once-Weekly Basal Insulin Fc Versus Insulin Degludec: A Systematic Review and Meta-Analysis. Endocrinol Diabetes Metab 2025",
     "pmid": "40509887",
     "url": "https://pubmed.ncbi.nlm.nih.gov/40509887/",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-09-23",
    "what": "FDA approved as Onswik",
    "source": "fda"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "fda",
    "bif",
    "qwint2"
   ],
   "class": "Once-weekly insulin-Fc fusion protein"
  },
  {
   "id": "elamipretide",
   "name": "Elamipretide",
   "aliases": [
    "Forzinity",
    "SS-31",
    "MTP-131"
   ],
   "sponsor": "Stealth BioTherapeutics",
   "target": "Cardiolipin in the inner mitochondrial membrane",
   "mechanism": "Binds cardiolipin and stabilises the membrane where cells make energy",
   "areas": [
    "rare-disease"
   ],
   "indications": [
    "Barth syndrome (approved, accelerated)",
    "Dry age-related macular degeneration (phase 3)"
   ],
   "phase": "approved-2025-26",
   "phase_note": "FDA accelerated approval September 19, 2025 for Barth syndrome; phase 3 in dry AMD",
   "phase_sources": [
    "label",
    "renew"
   ],
   "ncts": [
    "NCT03098797",
    "NCT06373731",
    "NCT07531251"
   ],
   "last_readout": {
    "date": "2025-09-19",
    "result": "Accelerated approval for muscle strength in Barth syndrome; continued approval depends on a confirmatory trial",
    "source": "first"
   },
   "next_milestone": {
    "what": "Primary completion of ReNEW, the phase 3 trial in dry age-related macular degeneration",
    "expected": "2027-08",
    "source": "renew"
   },
   "plain": "Mitochondria are the power plants inside our cells. Elamipretide is a tiny peptide, four building blocks long, that sticks to a fat in the power plant's wall and helps it work. It is approved for Barth syndrome, a rare inherited disease of muscle and heart.",
   "scientific": "Elamipretide is a cell-permeable tetrapeptide that concentrates in the inner mitochondrial membrane and binds cardiolipin, the phospholipid that is abnormal in Barth syndrome. FDA granted accelerated approval for improving muscle strength in Barth syndrome, with continued approval contingent on confirmatory trials. The ReNEW phase 3 trial tests subcutaneous elamipretide in dry age-related macular degeneration.",
   "entry": "ss-31",
   "sources": {
    "label": {
     "kind": "regulator",
     "label": "Forzinity (elamipretide) prescribing information, DailyMed set 146bf34c, version 10, effective December 10, 2025",
     "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=146bf34c-76f2-48db-ac07-fb29cce2cd75",
     "read": "2026-10-28"
    },
    "first": {
     "kind": "paper",
     "label": "Shirley M. Elamipretide: First Approval. Drugs 2025 (online December 3, 2025)",
     "pmid": "41335372",
     "url": "https://pubmed.ncbi.nlm.nih.gov/41335372/",
     "read": "2026-10-28"
    },
    "renew": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06373731 (ReNEW)",
     "url": "https://clinicaltrials.gov/study/NCT06373731",
     "nct": "NCT06373731",
     "read": "2026-10-28"
    },
    "taz": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT03098797 (TAZPOWER)",
     "url": "https://clinicaltrials.gov/study/NCT03098797",
     "nct": "NCT03098797",
     "read": "2026-10-28"
    },
    "taz4": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07531251 (4TAZPower)",
     "url": "https://clinicaltrials.gov/study/NCT07531251",
     "nct": "NCT07531251",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2025-09-19",
    "what": "FDA accelerated approval as Forzinity",
    "source": "first"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "first",
    "label",
    "renew"
   ],
   "class": "Mitochondria-targeted tetrapeptide"
  },
  {
   "id": "mazdutide",
   "name": "Mazdutide",
   "aliases": [
    "IBI362"
   ],
   "sponsor": "Innovent Biologics",
   "target": "GLP-1 and glucagon receptors",
   "mechanism": "Combines GLP-1 appetite and insulin effects with glucagon's effect on energy use and liver fat",
   "areas": [
    "obesity-diabetes"
   ],
   "indications": [
    "Weight management (approved in China)",
    "Type 2 diabetes"
   ],
   "phase": "approved-2025-26",
   "phase_note": "Approved in China, announced June 27, 2025; not approved in the US",
   "phase_sources": [
    "innovent"
   ],
   "ncts": [
    "NCT05607680",
    "NCT07255209"
   ],
   "last_readout": {
    "date": "2026-08-04",
    "result": "GLORY-2 (JAMA): clinically meaningful weight reduction against placebo in Chinese adults with moderate to severe obesity; vomiting, nausea and diarrhoea were common",
    "source": "glory2"
   },
   "next_milestone": {
    "what": "Primary completion of the phase 3 trial in Chinese adolescents",
    "expected": "2027-10-31",
    "source": "teen"
   },
   "plain": "Mazdutide is a weekly weight-loss injection that copies two hormones at once. One part, GLP-1, makes you feel full; the other, glucagon, helps the body use energy. China approved it in 2025; the US has not.",
   "scientific": "Mazdutide is a dual agonist of the glucagon and GLP-1 receptors. China's approval for chronic weight management rested mainly on the GLORY-1 phase 3 trial; GLORY-2 tested a higher dose in adults with moderate to severe obesity and reported clinically meaningful weight reduction, with vomiting, nausea and diarrhoea common. A phase 3 trial in Chinese adolescents is running.",
   "entry": "mazdutide",
   "sources": {
    "innovent": {
     "kind": "sponsor",
     "label": "Innovent Biologics: mazdutide approved by China's NMPA for chronic weight management (June 27, 2025)",
     "url": "https://www.biospace.com/press-releases/innovent-announces-mazdutide-first-dual-gcg-glp-1-receptor-agonist-received-approval-from-chinas-nmpa-for-chronic-weight-management",
     "date": "2025-06-27",
     "read": "2026-10-28"
    },
    "glory2": {
     "kind": "paper",
     "label": "Gao L, et al. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA 2026",
     "pmid": "42251595",
     "url": "https://pubmed.ncbi.nlm.nih.gov/42251595/",
     "read": "2026-10-28"
    },
    "glory1": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT05607680 (A Study of IBI362 in Participants With Obesity or Overweight)",
     "url": "https://clinicaltrials.gov/study/NCT05607680",
     "nct": "NCT05607680",
     "read": "2026-10-28"
    },
    "teen": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07255209 (A Study of IBI362 in Chinese Adolescents With Obesity or Overweight)",
     "url": "https://clinicaltrials.gov/study/NCT07255209",
     "nct": "NCT07255209",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2025-06-27",
    "what": "Approved in China for weight management",
    "source": "innovent"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "innovent",
    "glory2",
    "teen"
   ],
   "class": "GLP-1 and glucagon receptor dual agonist"
  },
  {
   "id": "ecnoglutide",
   "name": "Ecnoglutide",
   "aliases": [
    "XW003"
   ],
   "sponsor": "Sciwind Biosciences",
   "target": "GLP-1 receptor",
   "mechanism": "Activates the GLP-1 receptor while favouring the cAMP signal over receptor internalisation",
   "areas": [
    "obesity-diabetes"
   ],
   "indications": [
    "Type 2 diabetes and weight management (approved in China)",
    "Obstructive sleep apnoea",
    "Knee osteoarthritis"
   ],
   "phase": "approved-2025-26",
   "phase_note": "Approved in China for type 2 diabetes (January 2026) and weight management (March 6, 2026); not approved in the US",
   "phase_sources": [
    "sciwind"
   ],
   "ncts": [
    "NCT05813795",
    "NCT07387094"
   ],
   "last_readout": {
    "date": "2026-03-06",
    "result": "China approval for weight management on SLIMMER, a 48-week phase 3 in Chinese adults",
    "source": "sciwind"
   },
   "next_milestone": {
    "what": "Primary completion of the phase 3 trial in obstructive sleep apnoea without positive airway pressure",
    "expected": "2027-12-16",
    "source": "osa"
   },
   "plain": "Ecnoglutide is a weekly injection that acts like the gut hormone GLP-1, which makes people feel full and helps control blood sugar. It was designed to send its signal in a slightly different way. China approved it in 2026.",
   "scientific": "Ecnoglutide is a GLP-1 analogue biased toward cAMP signalling. In China it is approved for glycaemic control in type 2 diabetes, after trials such as EECOH-1, and for chronic weight management, on the SLIMMER phase 3 trial. Phase 3 trials continue in obstructive sleep apnoea and other conditions.",
   "entry": "ecnoglutide",
   "sources": {
    "sciwind": {
     "kind": "sponsor",
     "label": "Sciwind Biosciences: ecnoglutide injection approved by China's NMPA for chronic weight management (March 6, 2026)",
     "url": "https://www.biospace.com/press-releases/sciwind-biosciences-announces-ecnoglutide-injection-approved-by-chinas-national-medical-products-administration-nmpa-for-chronic-weight-management",
     "date": "2026-03-06",
     "read": "2026-10-28"
    },
    "slimmer": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT05813795 (A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity)",
     "url": "https://clinicaltrials.gov/study/NCT05813795",
     "nct": "NCT05813795",
     "read": "2026-10-28"
    },
    "osa": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07387094 (A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy)",
     "url": "https://clinicaltrials.gov/study/NCT07387094",
     "nct": "NCT07387094",
     "read": "2026-10-28"
    },
    "eecoh": {
     "kind": "paper",
     "label": "Zhu D, et al. Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1). Nat Commun 2026",
     "pmid": "41501026",
     "url": "https://pubmed.ncbi.nlm.nih.gov/41501026/",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-03-06",
    "what": "Approved in China for weight management",
    "source": "sciwind"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "sciwind",
    "eecoh",
    "osa"
   ],
   "class": "cAMP-biased GLP-1 receptor agonist"
  },
  {
   "id": "setmelanotide-aho",
   "name": "Setmelanotide (acquired hypothalamic obesity)",
   "aliases": [
    "Imcivree"
   ],
   "sponsor": "Rhythm Pharmaceuticals",
   "target": "MC4R",
   "mechanism": "Restores the brain's fullness signal downstream of a damaged hypothalamus",
   "areas": [
    "rare-disease",
    "obesity-diabetes",
    "endocrine"
   ],
   "indications": [
    "Acquired hypothalamic obesity from age 4 (new US indication)",
    "Congenital hypothalamic obesity (phase 3)"
   ],
   "phase": "approved-2025-26",
   "phase_note": "New indication: the US label in effect from April 1, 2026 includes acquired hypothalamic obesity; the drug itself was first approved in 2020",
   "phase_sources": [
    "label"
   ],
   "ncts": [
    "NCT05774756",
    "NCT06760546"
   ],
   "last_readout": {
    "date": "2026-07-09",
    "result": "TRANSCEND phase 3: significantly greater BMI and hunger reductions than placebo at 52 weeks in 120 people aged 4 to 66",
    "source": "transcend"
   },
   "next_milestone": {
    "what": "Primary completion of the phase 3 sub-study in congenital hypothalamic obesity",
    "expected": "2027-03-13",
    "source": "congenital"
   },
   "plain": "Some people gain a lot of weight after a brain tumour or injury damages the part of the brain that says 'I'm full'. Setmelanotide is a daily injection that switches on a fullness signal further down the line. Its US label now covers this kind of obesity.",
   "scientific": "Setmelanotide is a melanocortin-4 receptor agonist. In the TRANSCEND phase 3 trial in acquired hypothalamic obesity, it reduced BMI and hunger scores more than placebo at 52 weeks in participants aged 4 to 66. Skin hyperpigmentation, nausea, vomiting and headache were the most common adverse events, and serious adverse events were more frequent than on placebo. The label also covers Bardet-Biedl syndrome and POMC, PCSK1 or LEPR deficiency.",
   "entry": "setmelanotide",
   "sources": {
    "label": {
     "kind": "regulator",
     "label": "Imcivree (setmelanotide) US prescribing information, DailyMed set 70c3ccf7, version 14, effective April 1, 2026",
     "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70c3ccf7-4df0-4c75-ba07-fede9970c8d9",
     "read": "2026-10-28",
     "date": "2026-04-01"
    },
    "transcend": {
     "kind": "paper",
     "label": "Miller JL, et al. Setmelanotide for the Treatment of Acquired Hypothalamic Obesity. N Engl J Med 2026;395:138-150",
     "pmid": "42418774",
     "url": "https://pubmed.ncbi.nlm.nih.gov/42418774/",
     "read": "2026-10-28"
    },
    "congenital": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06760546 (A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756))",
     "url": "https://clinicaltrials.gov/study/NCT06760546",
     "nct": "NCT06760546",
     "read": "2026-10-28"
    },
    "tr_reg": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT05774756 (A Trial of Setmelanotide in Acquired Hypothalamic Obesity)",
     "url": "https://clinicaltrials.gov/study/NCT05774756",
     "nct": "NCT05774756",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-07-09",
    "what": "TRANSCEND phase 3 published",
    "source": "transcend"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "transcend",
    "label"
   ],
   "class": "Cyclic melanocortin-4 receptor agonist"
  },
  {
   "id": "lutetium-psma-617",
   "name": "Lutetium Lu 177 vipivotide tetraxetan",
   "aliases": [
    "Pluvicto",
    "177Lu-PSMA-617"
   ],
   "sponsor": "Novartis",
   "target": "Prostate-specific membrane antigen (PSMA)",
   "mechanism": "Carries a beta-emitting radioactive atom to PSMA on prostate cancer cells",
   "areas": [
    "oncology"
   ],
   "indications": [
    "PSMA-positive metastatic prostate cancer, now including hormone-sensitive disease with ADT plus an androgen-pathway inhibitor"
   ],
   "phase": "approved-2025-26",
   "phase_note": "New indication: the label effective August 12, 2026 adds androgen-pathway-naive or -sensitive disease; first approved 2022",
   "phase_sources": [
    "label"
   ],
   "ncts": [
    "NCT04720157",
    "NCT04689828",
    "NCT05803941"
   ],
   "last_readout": {
    "date": "2026-08-06",
    "result": "PSMAddition: adding it to ADT plus an androgen-pathway inhibitor cut the risk of radiographic progression or death by 28% (HR 0.72)",
    "source": "psmaddition"
   },
   "next_milestone": {
    "what": "Primary completion of the long-term safety study",
    "expected": "2033-07-20",
    "source": "ltfu"
   },
   "plain": "This drug is a homing missile for prostate cancer. A molecule that sticks to a protein called PSMA on cancer cells carries a speck of radioactive lutetium, which damages the cancer from close range. In 2026 its use was widened to an earlier stage of the disease.",
   "scientific": "Lutetium Lu 177 vipivotide tetraxetan is a PSMA-targeted radioligand: a PSMA-binding molecule carrying the beta emitter lutetium-177. In PSMAddition, a phase 3 trial in PSMA-positive metastatic hormone-sensitive prostate cancer, adding it to androgen deprivation plus an androgen-pathway inhibitor improved radiographic progression-free survival (HR 0.72). Grade 3 or worse adverse events were more frequent with the combination, without unexpected safety findings. The August 2026 label covers this use.",
   "entry": "vipivotide-tetraxetan",
   "sources": {
    "label": {
     "kind": "regulator",
     "label": "Pluvicto US prescribing information, DailyMed set 14908037, version 5, effective August 12, 2026",
     "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14908037-2892-4d98-a053-253ce35afb1a",
     "read": "2026-10-28",
     "date": "2026-08-12"
    },
    "psmaddition": {
     "kind": "paper",
     "label": "Tagawa ST, et al. [177Lu]Lu-PSMA-617 in PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 trial. Lancet 2026",
     "pmid": "42561994",
     "url": "https://pubmed.ncbi.nlm.nih.gov/42561994/",
     "read": "2026-10-28"
    },
    "ltfu": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT05803941 (Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer)",
     "url": "https://clinicaltrials.gov/study/NCT05803941",
     "nct": "NCT05803941",
     "read": "2026-10-28"
    },
    "pa_reg": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT04720157 (PSMAddition)",
     "url": "https://clinicaltrials.gov/study/NCT04720157",
     "nct": "NCT04720157",
     "read": "2026-10-28"
    },
    "pf_reg": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT04689828 (PSMAfore)",
     "url": "https://clinicaltrials.gov/study/NCT04689828",
     "nct": "NCT04689828",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-08-12",
    "what": "US label extended to hormone-sensitive metastatic disease",
    "source": "label"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "psmaddition",
    "label"
   ],
   "class": "Peptidomimetic radioligand"
  },
  {
   "id": "cagrisema",
   "name": "CagriSema",
   "aliases": [
    "cagrilintide and semaglutide"
   ],
   "sponsor": "Novo Nordisk",
   "target": "Amylin/calcitonin receptors and GLP-1 receptor",
   "mechanism": "Two satiety hormones' signals in one weekly injection",
   "areas": [
    "obesity-diabetes"
   ],
   "indications": [
    "Weight management (filed)",
    "Type 2 diabetes (phase 3)"
   ],
   "phase": "filed",
   "phase_note": "New Drug Application submitted to FDA in December 2025; Novo said FDA would review it in 2026",
   "phase_sources": [
    "nda"
   ],
   "ncts": [
    "NCT05567796",
    "NCT06534411"
   ],
   "last_readout": {
    "date": "2025-06-22",
    "result": "REDEFINE 1 (NEJM 2025): weight fell 20.4% against 3.0% on placebo at 68 weeks",
    "source": "redefine1"
   },
   "next_milestone": {
    "what": "FDA decision on the weight-management application",
    "expected": "2026",
    "source": "nda"
   },
   "plain": "CagriSema puts two weight-loss hormone copies in one weekly injection: semaglutide, the drug in Wegovy, and cagrilintide, a copy of the fullness hormone amylin. Novo Nordisk has asked the FDA to approve it.",
   "scientific": "CagriSema combines cagrilintide, a long-acting amylin analogue, with the GLP-1 receptor agonist semaglutide. In REDEFINE 1, a 68-week phase 3a trial of 3,417 adults, mean weight change was -20.4% against -3.0% on placebo, and gastrointestinal adverse events affected 79.6% against 39.9%. Novo Nordisk filed the obesity application with FDA in December 2025; the REIMAGINE trials cover type 2 diabetes.",
   "entry": "cagrisema",
   "sources": {
    "nda": {
     "kind": "sponsor",
     "label": "Novo Nordisk: files for FDA approval of CagriSema (December 18, 2025)",
     "url": "https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916470",
     "date": "2025-12-18",
     "read": "2026-10-28"
    },
    "redefine1": {
     "kind": "paper",
     "label": "Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2025;393:635-647",
     "pmid": "40544433",
     "url": "https://pubmed.ncbi.nlm.nih.gov/40544433/",
     "read": "2026-10-28"
    },
    "r1": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT05567796 (REDEFINE 1)",
     "url": "https://clinicaltrials.gov/study/NCT05567796",
     "nct": "NCT05567796",
     "read": "2026-10-28"
    },
    "r5": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06534411 (REIMAGINE 5)",
     "url": "https://clinicaltrials.gov/study/NCT06534411",
     "nct": "NCT06534411",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2025-12-18",
    "what": "Submitted to FDA",
    "source": "nda"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "redefine1",
    "nda",
    "r5"
   ],
   "class": "Fixed combination: amylin analogue plus GLP-1 agonist"
  },
  {
   "id": "lutetium-edotreotide",
   "name": "Lutetium Lu 177 edotreotide",
   "aliases": [
    "ITM-11",
    "177Lu-DOTATOC"
   ],
   "sponsor": "ITM Isotope Technologies Munich",
   "target": "Somatostatin receptor 2",
   "mechanism": "Carries lutetium-177 to neuroendocrine tumour cells that display somatostatin receptors",
   "areas": [
    "oncology"
   ],
   "indications": [
    "Gastroenteropancreatic neuroendocrine tumours (filed)"
   ],
   "phase": "filed",
   "phase_note": "NDA accepted with an August 28, 2026 goal date; FDA issued a complete response letter on August 7, 2026 citing manufacturing (CMC) and a third-party facility, not the clinical data; ITM plans to resubmit",
   "phase_sources": [
    "crl",
    "nda"
   ],
   "ncts": [
    "NCT03049189",
    "NCT04919226"
   ],
   "last_readout": {
    "date": "2026-08-07",
    "result": "Complete response letter on manufacturing grounds; no clinical or safety concerns raised, the company says",
    "source": "crl"
   },
   "next_milestone": {
    "what": "Primary completion of COMPOSE, the second phase 3 trial (grade 2-3 tumours)",
    "expected": "2027-06",
    "source": "compose"
   },
   "plain": "Neuroendocrine tumours often carry a 'docking site' for the hormone somatostatin. This drug is a somatostatin look-alike carrying a radioactive atom, so it delivers radiation straight to the tumour. The FDA asked for manufacturing fixes before it can approve it.",
   "scientific": "Lutetium Lu 177 edotreotide (DOTATOC) is a somatostatin-analogue radioligand. In the COMPETE phase 3 trial in grade 1-2 gastroenteropancreatic neuroendocrine tumours, median progression-free survival was 23.9 months against 14.1 months on everolimus (HR 0.67). FDA's August 2026 complete response letter concerned chemistry, manufacturing and controls and a third-party facility, according to the company. COMPOSE tests it against standard therapy in higher-grade tumours.",
   "entry": "edotreotide",
   "sources": {
    "crl": {
     "kind": "sponsor",
     "label": "ITM: receives complete response letter for 177Lu-edotreotide (ITM-11) (August 10, 2026)",
     "url": "https://www.itm-radiopharma.com/news/press-releases/press-releases-detail/itm-receives-complete-response-letter-for-177lu-edotreotide-itm-11-763/",
     "date": "2026-08-10",
     "read": "2026-10-28"
    },
    "nda": {
     "kind": "sponsor",
     "label": "ITM: FDA acceptance of NDA and PDUFA date for n.c.a. 177Lu-edotreotide (November 13, 2025)",
     "url": "https://www.itm-radiopharma.com/news/press-releases/press-releases-detail/itm-announces-fda-acceptance-of-new-drug-application-nda-and-pdufa-date-for-n-c-a-177lu-edotreotide-itm-11-in-gastroenteropancreatic-neuroendocrine-tumors-gep-nets-747/",
     "date": "2025-11-13",
     "read": "2026-10-28"
    },
    "compete": {
     "kind": "paper",
     "label": "Walter T, et al. [177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3 trial. Lancet 2026",
     "pmid": "42392118",
     "url": "https://pubmed.ncbi.nlm.nih.gov/42392118/",
     "read": "2026-10-28"
    },
    "compose": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT04919226 (COMPOSE)",
     "url": "https://clinicaltrials.gov/study/NCT04919226",
     "nct": "NCT04919226",
     "read": "2026-10-28"
    },
    "compete_reg": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT03049189 (COMPETE)",
     "url": "https://clinicaltrials.gov/study/NCT03049189",
     "nct": "NCT03049189",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-08-07",
    "what": "FDA complete response letter (manufacturing); resubmission planned",
    "source": "crl"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "compete",
    "crl",
    "compose"
   ],
   "class": "Somatostatin-analogue radioligand"
  },
  {
   "id": "retatrutide",
   "name": "Retatrutide",
   "aliases": [
    "LY3437943"
   ],
   "sponsor": "Eli Lilly",
   "target": "GIP, GLP-1 and glucagon receptors",
   "mechanism": "One peptide that activates three hormone receptors involved in appetite, insulin and energy use",
   "areas": [
    "obesity-diabetes"
   ],
   "indications": [
    "Obesity",
    "Obstructive sleep apnoea",
    "Knee osteoarthritis pain",
    "Type 2 diabetes"
   ],
   "phase": "phase 3",
   "phase_note": "Phase 3 complete for the first filings; Lilly plans a US Biologics License Application in the first quarter of 2027. Not approved; Lilly says it cannot legally be sold for human use",
   "phase_sources": [
    "triumph1_reg",
    "q2"
   ],
   "ncts": [
    "NCT05929066",
    "NCT05882045",
    "NCT06297603",
    "NCT07629401",
    "NCT06260722"
   ],
   "last_readout": {
    "date": "2026-10-28",
    "result": "TRANSCEND-T2D-2 (Lilly topline, not yet published): HbA1c fell 2.2 points on 9 mg and 12 mg against 1.8 on semaglutide 2 mg, and weight 19.5% and 20.9% against 9.4%, at 80 weeks (1,298 adults with type 2 diabetes)",
    "source": "tt2rel"
   },
   "next_milestone": {
    "what": "Planned US submission for obesity, sleep apnoea and knee osteoarthritis pain",
    "expected": "2027-Q1",
    "source": "q2"
   },
   "plain": "Retatrutide is an experimental weekly injection that copies three hormones at once. Together they cut hunger and change how the body uses energy, and in a large trial people lost about a quarter of their weight. It is not approved, and Lilly says it cannot legally be sold for human use.",
   "scientific": "Retatrutide is a single peptide agonist of the GIP, GLP-1 and glucagon receptors. In TRIUMPH-1, an 80-week phase 3 trial, it met co-primary endpoints for body weight, knee osteoarthritis pain and the apnoea-hypopnoea index; gastrointestinal events were the most common adverse effects. Lilly plans to submit for US approval in the first quarter of 2027 and runs a single-patient expanded-access programme before then.",
   "entry": "retatrutide",
   "sources": {
    "triumph1": {
     "kind": "paper",
     "label": "Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med 2026 (TRIUMPH-1)",
     "pmid": "42814954",
     "url": "https://pubmed.ncbi.nlm.nih.gov/42814954/",
     "read": "2026-10-28"
    },
    "q2": {
     "kind": "sponsor",
     "label": "Eli Lilly: second-quarter 2026 financial results (August 5, 2026): BLA submission planned in the first quarter of 2027",
     "url": "https://investor.lilly.com/news-releases/news-release-details/lilly-reports-second-quarter-2026-financial-results-raises-full",
     "date": "2026-08-05",
     "read": "2026-10-28"
    },
    "triumph1_reg": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT05929066 (TRIUMPH-1)",
     "url": "https://clinicaltrials.gov/study/NCT05929066",
     "nct": "NCT05929066",
     "read": "2026-10-28"
    },
    "triumph3": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT05882045 (TRIUMPH-3)",
     "url": "https://clinicaltrials.gov/study/NCT05882045",
     "nct": "NCT05882045",
     "read": "2026-10-28"
    },
    "renal": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06297603 (Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3))",
     "url": "https://clinicaltrials.gov/study/NCT06297603",
     "nct": "NCT06297603",
     "read": "2026-10-28"
    },
    "ea": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07629401 (Pre-approval Expanded Access of Retatrutide (LY3437943))",
     "url": "https://clinicaltrials.gov/study/NCT07629401",
     "nct": "NCT07629401",
     "read": "2026-10-28"
    },
    "tr1rel": {
     "kind": "sponsor",
     "label": "Eli Lilly: retatrutide delivered powerful weight loss in pivotal phase 3 obesity trial (May 21, 2026)",
     "url": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss",
     "date": "2026-05-21",
     "read": "2026-10-28"
    },
    "transcend2": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06260722 (TRANSCEND-T2D-2)",
     "url": "https://clinicaltrials.gov/study/NCT06260722",
     "nct": "NCT06260722",
     "read": "2026-11-03"
    },
    "tt2rel": {
     "kind": "sponsor",
     "label": "Eli Lilly: retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial (October 28, 2026)",
     "url": "https://investor.lilly.com/node/55186",
     "date": "2026-10-28",
     "read": "2026-11-03"
    }
   },
   "changed": {
    "date": "2026-10-28",
    "what": "TRANSCEND-T2D-2 topline: retatrutide beat semaglutide 2 mg on HbA1c and weight",
    "source": "tt2rel"
   },
   "last_checked": "2026-11-03",
   "explainer_sources": [
    "triumph1",
    "q2",
    "ea",
    "tr1rel"
   ],
   "class": "GIP, GLP-1 and glucagon receptor triple agonist"
  },
  {
   "id": "survodutide",
   "name": "Survodutide",
   "aliases": [
    "BI 456906"
   ],
   "sponsor": "Boehringer Ingelheim (licensed from Zealand Pharma)",
   "target": "Glucagon and GLP-1 receptors",
   "mechanism": "Pairs GLP-1 satiety with glucagon-driven energy use and liver-fat loss",
   "areas": [
    "obesity-diabetes",
    "cardiometabolic"
   ],
   "indications": [
    "Obesity",
    "Type 2 diabetes with obesity",
    "MASH (fatty liver disease with inflammation)"
   ],
   "phase": "phase 3",
   "phase_note": "Phase 3 programme SYNCHRONIZE (obesity) and LIVERAGE (MASH)",
   "phase_sources": [
    "s2_reg",
    "cvot"
   ],
   "ncts": [
    "NCT06066515",
    "NCT06066528",
    "NCT06077864",
    "NCT07754461"
   ],
   "last_readout": {
    "date": "2026-10-01",
    "result": "SYNCHRONIZE-2 (NEJM): weight changed -8.2% and -9.8% on the two doses against -3.9% on placebo at 76 weeks",
    "source": "s2"
   },
   "next_milestone": {
    "what": "Primary completion of a new phase 3 trial in type 2 diabetes",
    "expected": "2028-01-17",
    "source": "t2d"
   },
   "plain": "Survodutide is a weekly injection being tested for weight loss and fatty liver disease. It copies two hormones: one that makes you feel full and one that acts on how the body and liver use energy. Its large trials have reported, but it is not approved anywhere.",
   "scientific": "Survodutide is a dual agonist of the glucagon and GLP-1 receptors. SYNCHRONIZE-1 (obesity without diabetes) and SYNCHRONIZE-2 (with type 2 diabetes) met their weight endpoints over 76 weeks, with gastrointestinal adverse events in most participants on the drug. The SYNCHRONIZE-CVOT cardiovascular safety trial reached primary completion in June 2026, and LIVERAGE trials test it in MASH.",
   "entry": "survodutide",
   "sources": {
    "s2": {
     "kind": "paper",
     "label": "Wharton S, et al. Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes. N Engl J Med 2026 (SYNCHRONIZE-2)",
     "pmid": "42820639",
     "url": "https://pubmed.ncbi.nlm.nih.gov/42820639/",
     "read": "2026-10-28"
    },
    "s1": {
     "kind": "paper",
     "label": "le Roux CW, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity. N Engl J Med 2026;395:776-787 (SYNCHRONIZE-1)",
     "pmid": "42253238",
     "url": "https://pubmed.ncbi.nlm.nih.gov/42253238/",
     "read": "2026-10-28"
    },
    "s2_reg": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06066528 (SYNCHRONIZE™-2)",
     "url": "https://clinicaltrials.gov/study/NCT06066528",
     "nct": "NCT06066528",
     "read": "2026-10-28"
    },
    "s1_reg": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06066515 (SYNCHRONIZE™-1)",
     "url": "https://clinicaltrials.gov/study/NCT06066515",
     "nct": "NCT06066515",
     "read": "2026-10-28"
    },
    "cvot": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06077864 (A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT))",
     "url": "https://clinicaltrials.gov/study/NCT06077864",
     "nct": "NCT06077864",
     "read": "2026-10-28"
    },
    "t2d": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07754461 (A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar)",
     "url": "https://clinicaltrials.gov/study/NCT07754461",
     "nct": "NCT07754461",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-10-01",
    "what": "SYNCHRONIZE-2 published",
    "source": "s2"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "s1",
    "s2",
    "cvot"
   ],
   "class": "Glucagon and GLP-1 receptor dual agonist"
  },
  {
   "id": "maridebart-cafraglutide",
   "name": "Maridebart cafraglutide",
   "aliases": [
    "MariTide",
    "AMG 133"
   ],
   "sponsor": "Amgen",
   "target": "GLP-1 receptor (agonist) and GIP receptor (antagonist)",
   "mechanism": "Two GLP-1 agonist peptides attached to an antibody that blocks the GIP receptor; dosed monthly",
   "areas": [
    "obesity-diabetes",
    "cardiometabolic"
   ],
   "indications": [
    "Obesity",
    "Type 2 diabetes",
    "Obstructive sleep apnoea",
    "Heart failure"
   ],
   "phase": "phase 3",
   "phase_note": "MARITIME phase 3 programme",
   "phase_sources": [
    "japan"
   ],
   "ncts": [
    "NCT05669599",
    "NCT06987695",
    "NCT07225686"
   ],
   "last_readout": {
    "date": "2025-06-23",
    "result": "Phase 2 (NEJM): weight fell 12.3% to 16.2% against 2.5% on placebo at 52 weeks in people without diabetes",
    "source": "p2"
   },
   "next_milestone": {
    "what": "Primary completion of MARITIME-3-J in Japan, the earliest registered phase 3 completion",
    "expected": "2027-04-27",
    "source": "japan"
   },
   "plain": "MariTide joins two GLP-1-like peptides to an antibody. The antibody makes it last long enough for a monthly injection, and it also blocks a second hormone receptor called GIP. It is in large trials for obesity.",
   "scientific": "Maridebart cafraglutide is a long-acting peptide-antibody conjugate that combines GLP-1 receptor agonism with GIP receptor antagonism. In a 52-week phase 2 trial with dosing every four weeks, it produced substantial weight reduction in people with obesity with or without type 2 diabetes. Gastrointestinal adverse events were common and less frequent with dose escalation and a lower starting dose.",
   "entry": "maridebart-cafraglutide",
   "sources": {
    "p2": {
     "kind": "paper",
     "label": "Jastreboff AM, et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. N Engl J Med 2025;393:843-857",
     "pmid": "40549887",
     "url": "https://pubmed.ncbi.nlm.nih.gov/40549887/",
     "read": "2026-10-28"
    },
    "japan": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06987695 (MARITIME-3-J)",
     "url": "https://clinicaltrials.gov/study/NCT06987695",
     "nct": "NCT06987695",
     "read": "2026-10-28"
    },
    "p2_reg": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT05669599 (Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus)",
     "url": "https://clinicaltrials.gov/study/NCT05669599",
     "nct": "NCT05669599",
     "read": "2026-10-28"
    },
    "osa": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07225686 (MARITIME-OSA-1)",
     "url": "https://clinicaltrials.gov/study/NCT07225686",
     "nct": "NCT07225686",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2025-06-23",
    "what": "Phase 2 published in NEJM",
    "source": "p2"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "p2",
    "japan"
   ],
   "class": "Peptide-antibody conjugate"
  },
  {
   "id": "eloralintide",
   "name": "Eloralintide",
   "aliases": [
    "LY3841136",
    "EloraTZP (with tirzepatide)"
   ],
   "sponsor": "Eli Lilly",
   "target": "Amylin receptors",
   "mechanism": "Mimics amylin, a hormone released with insulin that slows the stomach and signals fullness",
   "areas": [
    "obesity-diabetes"
   ],
   "indications": [
    "Obesity",
    "Knee osteoarthritis pain",
    "Obstructive sleep apnoea",
    "With tirzepatide as EloraTZP"
   ],
   "phase": "phase 3",
   "phase_note": "Five ENLIGHTEN phase 3 trials recruiting; two EloraTZP phase 3 trials registered",
   "phase_sources": [
    "enl1"
   ],
   "ncts": [
    "NCT06230523",
    "NCT06603571",
    "NCT07321886",
    "NCT07881432"
   ],
   "last_readout": {
    "date": "2025-11-06",
    "result": "Phase 2 (Lancet): dose-dependent weight loss over 48 weeks against -0.4% on placebo; nausea and fatigue the common adverse events",
    "source": "p2"
   },
   "next_milestone": {
    "what": "Primary completion of ENLIGHTEN-1 in obesity without diabetes",
    "expected": "2028-03",
    "source": "enl1"
   },
   "plain": "Amylin is a hormone your pancreas releases alongside insulin after a meal; it helps tell your brain you have eaten enough. Eloralintide is a long-lasting weekly copy of it being tested for weight loss, alone and paired with tirzepatide.",
   "scientific": "Eloralintide is a selective amylin receptor agonist. In a 48-week phase 2 trial it produced dose-dependent weight reduction against placebo, with nausea and fatigue the most common adverse events. Lilly is testing it alone in the ENLIGHTEN phase 3 trials and with tirzepatide (EloraTZP) in AMPLIFY.",
   "entry": "eloralintide",
   "sources": {
    "p2": {
     "kind": "paper",
     "label": "Billings LK, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2 trial. Lancet 2025",
     "pmid": "41207310",
     "url": "https://pubmed.ncbi.nlm.nih.gov/41207310/",
     "read": "2026-10-28"
    },
    "enl1": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07321886 (ENLIGHTEN-1)",
     "url": "https://clinicaltrials.gov/study/NCT07321886",
     "nct": "NCT07321886",
     "read": "2026-10-28"
    },
    "amp1": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07881432 (AMPLIFY-1)",
     "url": "https://clinicaltrials.gov/study/NCT07881432",
     "nct": "NCT07881432",
     "read": "2026-10-28"
    },
    "p2_reg": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06230523 (A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight)",
     "url": "https://clinicaltrials.gov/study/NCT06230523",
     "nct": "NCT06230523",
     "read": "2026-10-28"
    },
    "tzp": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06603571 (A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes)",
     "url": "https://clinicaltrials.gov/study/NCT06603571",
     "nct": "NCT06603571",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-02-06",
    "what": "ENLIGHTEN-1 phase 3 started",
    "source": "enl1"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "p2",
    "enl1",
    "amp1"
   ],
   "class": "Selective amylin receptor agonist"
  },
  {
   "id": "amycretin",
   "name": "Amycretin",
   "aliases": [
    "NNC0487-0111"
   ],
   "sponsor": "Novo Nordisk",
   "target": "GLP-1 and amylin receptors",
   "mechanism": "One peptide that activates both GLP-1 and amylin receptors; weekly injection and an oral form",
   "areas": [
    "obesity-diabetes"
   ],
   "indications": [
    "Obesity",
    "Obstructive sleep apnoea",
    "Type 2 diabetes"
   ],
   "phase": "phase 3",
   "phase_note": "AMAZE phase 3 programme registered under NNC0487-0111 from April 2026",
   "phase_sources": [
    "amaze12"
   ],
   "ncts": [
    "NCT07503210",
    "NCT07571005"
   ],
   "last_readout": {
    "date": "2025-06-20",
    "result": "Phase 1b/2a (Lancet): weight fell 24.3% against 1.1% on placebo at 36 weeks in the highest-dose group",
    "source": "p1b"
   },
   "next_milestone": {
    "what": "Primary completion of AMAZE 12",
    "expected": "2028-06-06",
    "source": "amaze12"
   },
   "plain": "Amycretin is one molecule that does the job of two fullness hormones, GLP-1 and amylin. Early trials showed large weight loss, and big trials started in 2026.",
   "scientific": "Amycretin is a unimolecular agonist of the GLP-1 and amylin receptors, rather than a combination of two molecules as in CagriSema. In a subcutaneous phase 1b/2a study, weight fell substantially more than on placebo, and gastrointestinal events were frequent, at rates similar to early studies of each agonist class. Novo Nordisk registers the AMAZE phase 3 trials under its code NNC0487-0111.",
   "entry": "amycretin",
   "sources": {
    "p1b": {
     "kind": "paper",
     "label": "Dahl K, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: phase 1b/2a. Lancet 2025",
     "pmid": "40550231",
     "url": "https://pubmed.ncbi.nlm.nih.gov/40550231/",
     "read": "2026-10-28"
    },
    "amaze12": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07503210 (AMAZE 12)",
     "url": "https://clinicaltrials.gov/study/NCT07503210",
     "nct": "NCT07503210",
     "read": "2026-10-28"
    },
    "amaze3": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07571005 (AMAZE 3)",
     "url": "https://clinicaltrials.gov/study/NCT07571005",
     "nct": "NCT07571005",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-04-21",
    "what": "AMAZE phase 3 programme began (AMAZE 12 start date)",
    "source": "amaze12"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "p1b",
    "amaze12"
   ],
   "class": "Unimolecular GLP-1 and amylin receptor agonist"
  },
  {
   "id": "cagrilintide",
   "name": "Cagrilintide",
   "aliases": [
    "NN9838"
   ],
   "sponsor": "Novo Nordisk",
   "target": "Amylin and calcitonin receptors",
   "mechanism": "Weekly amylin mimic that signals fullness",
   "areas": [
    "obesity-diabetes"
   ],
   "indications": [
    "Weight management on its own (phase 3)"
   ],
   "phase": "phase 3",
   "phase_note": "Phase 3 trials of cagrilintide alone, separate from CagriSema",
   "phase_sources": [
    "renew1"
   ],
   "ncts": [
    "NCT07220642"
   ],
   "last_readout": {
    "date": "2021-11-16",
    "result": "Phase 2 (Lancet): significant, dose-dependent weight reduction against placebo over 26 weeks",
    "source": "p2"
   },
   "next_milestone": {
    "what": "Primary completion of RENEW 1, a phase 3 trial of cagrilintide alone",
    "expected": "2027-05-11",
    "source": "renew1"
   },
   "plain": "Cagrilintide is a weekly copy of amylin, a fullness hormone. It is best known as half of CagriSema, but Novo Nordisk is also testing it on its own.",
   "scientific": "Cagrilintide is a long-acting amylin analogue. As monotherapy it produced significant weight reduction against placebo in a phase 2 trial, with gastrointestinal events and injection-site reactions the most frequent adverse events. A stand-alone phase 3 trial, RENEW 1, began in November 2025.",
   "entry": "cagrilintide",
   "sources": {
    "p2": {
     "kind": "paper",
     "label": "Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a phase 2 trial. Lancet 2021",
     "pmid": "34798060",
     "url": "https://pubmed.ncbi.nlm.nih.gov/34798060/",
     "read": "2026-10-28"
    },
    "renew1": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07220642 (RENEW 1)",
     "url": "https://clinicaltrials.gov/study/NCT07220642",
     "nct": "NCT07220642",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2025-11-05",
    "what": "RENEW 1 phase 3 started",
    "source": "renew1"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "p2",
    "renew1"
   ],
   "class": "Long-acting amylin analogue"
  },
  {
   "id": "petrelintide",
   "name": "Petrelintide",
   "aliases": [
    "ZP8396"
   ],
   "sponsor": "Zealand Pharma with Roche",
   "target": "Amylin receptors",
   "mechanism": "A weekly amylin copy designed for gentler stomach side effects",
   "areas": [
    "obesity-diabetes"
   ],
   "indications": [
    "Obesity",
    "Obesity with type 2 diabetes"
   ],
   "phase": "phase 3",
   "phase_note": "Roche started three phase 3 trials (ZUPREME-3, -4 and a third) on September 30, 2026",
   "phase_sources": [
    "z3",
    "z4"
   ],
   "ncts": [
    "NCT06662539",
    "NCT07843498",
    "NCT07843485"
   ],
   "last_readout": {
    "date": "2026-09-29",
    "result": "ZUPREME 1 (Lancet Diabetes Endocrinol): 7.9% to 9.8% weight loss across doses against 1.7% on placebo at 28 weeks; the top three doses performed about the same",
    "source": "z1"
   },
   "next_milestone": {
    "what": "Primary completion of ZUPREME-4 (obesity with type 2 diabetes)",
    "expected": "2028-10-20",
    "source": "z4"
   },
   "plain": "Petrelintide is another weekly copy of the fullness hormone amylin. A mid-size trial showed steady weight loss with mostly mild nausea, and the biggest trials started in autumn 2026.",
   "scientific": "Petrelintide is a human amylin analogue for weekly dosing. In ZUPREME 1, weight loss at the 28-week primary endpoint was similar across the three highest doses, and nausea, mostly mild and during dose escalation, was the main adverse event. Roche, which co-develops it with Zealand, started phase 3 trials in September 2026.",
   "entry": "petrelintide",
   "sources": {
    "z1": {
     "kind": "paper",
     "label": "Garvey WT, et al. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a phase 2 trial. Lancet Diabetes Endocrinol 2026",
     "pmid": "42810355",
     "url": "https://pubmed.ncbi.nlm.nih.gov/42810355/",
     "read": "2026-10-28"
    },
    "z3": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07843498 (ZUPREME-3)",
     "url": "https://clinicaltrials.gov/study/NCT07843498",
     "nct": "NCT07843498",
     "read": "2026-10-28"
    },
    "z4": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07843485 (ZUPREME-4)",
     "url": "https://clinicaltrials.gov/study/NCT07843485",
     "nct": "NCT07843485",
     "read": "2026-10-28"
    },
    "z1_reg": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06662539 (ZUPREME)",
     "url": "https://clinicaltrials.gov/study/NCT06662539",
     "nct": "NCT06662539",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-09-30",
    "what": "Phase 3 trials started",
    "source": "z3"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "z1",
    "z3",
    "z4"
   ],
   "class": "Long-acting human amylin analogue"
  },
  {
   "id": "enicepatide",
   "name": "Enicepatide",
   "aliases": [
    "CT-388",
    "RO7795068"
   ],
   "sponsor": "Roche (from Carmot Therapeutics)",
   "target": "GLP-1 and GIP receptors",
   "mechanism": "Activates both incretin receptors while limiting receptor internalisation",
   "areas": [
    "obesity-diabetes"
   ],
   "indications": [
    "Obesity",
    "Obesity with type 2 diabetes"
   ],
   "phase": "phase 3",
   "phase_note": "Enith phase 3 programme started March 2026; a head-to-head with tirzepatide is registered",
   "phase_sources": [
    "enith1"
   ],
   "ncts": [
    "NCT07351045",
    "NCT07351058",
    "NCT06628362"
   ],
   "last_readout": {
    "date": "2025-11-28",
    "result": "Phase 1b and preclinical report (Mol Metab): cAMP-biased dual agonism reduced weight and improved glycaemia in participants with obesity",
    "source": "p1"
   },
   "next_milestone": {
    "what": "Primary completion of Enith1 (obesity without diabetes)",
    "expected": "2028-07-24",
    "source": "enith1"
   },
   "plain": "Enicepatide is a weekly injection that, like tirzepatide, copies two gut hormones, GLP-1 and GIP. It was built to switch the receptors on without making them shut down as quickly. Its large trials began in 2026.",
   "scientific": "Enicepatide (CT-388) is a unimolecular peptide agonist of the GLP-1 and GIP receptors that is cAMP-signal-biased, with minimal receptor internalisation. Preclinical and early clinical work reported weight loss and improved glycaemic control. Roche sponsors the Enith phase 3 trials.",
   "entry": "enicepatide",
   "sources": {
    "p1": {
     "kind": "paper",
     "label": "Chakravarthy MV, et al. Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, in preclinical models and participants with obesity. Mol Metab 2025",
     "pmid": "41319798",
     "url": "https://pubmed.ncbi.nlm.nih.gov/41319798/",
     "read": "2026-10-28"
    },
    "enith1": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07351045 (Enith1)",
     "url": "https://clinicaltrials.gov/study/NCT07351045",
     "nct": "NCT07351045",
     "read": "2026-10-28"
    },
    "enith2": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07351058 (Enith2)",
     "url": "https://clinicaltrials.gov/study/NCT07351058",
     "nct": "NCT07351058",
     "read": "2026-10-28"
    },
    "p2": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06628362 (A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus)",
     "url": "https://clinicaltrials.gov/study/NCT06628362",
     "nct": "NCT06628362",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-03-16",
    "what": "Phase 3 Enith1 started",
    "source": "enith1"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "p1",
    "enith1"
   ],
   "class": "Signalling-biased GLP-1 and GIP receptor dual agonist"
  },
  {
   "id": "olatorepatide",
   "name": "Olatorepatide",
   "aliases": [
    "HS-20094"
   ],
   "sponsor": "Hansoh Pharma (China); Regeneron (outside China)",
   "target": "GLP-1 and GIP receptors",
   "mechanism": "Weekly incretin dual agonist in the tirzepatide class",
   "areas": [
    "obesity-diabetes",
    "dermatology"
   ],
   "indications": [
    "Obesity",
    "Type 2 diabetes",
    "Hidradenitis suppurativa (phase 2)"
   ],
   "phase": "phase 3",
   "phase_note": "Phase 3 completed in China (LIGHTEN); Regeneron's global phase 3 RISE-1 registered",
   "phase_sources": [
    "lighten_reg",
    "rise1"
   ],
   "ncts": [
    "NCT06839664",
    "NCT07896265",
    "NCT07431086"
   ],
   "last_readout": {
    "date": "2026-10-02",
    "result": "LIGHTEN (604 Chinese adults): weight fell 11.8%, 17.0% and 18.7% on three doses against 2.5% on placebo at 48 weeks, counting everyone randomised (company release)",
    "source": "hansoh"
   },
   "next_milestone": {
    "what": "Primary completion of Regeneron's US phase 2 in overweight or obesity",
    "expected": "2026-11-13",
    "source": "us2"
   },
   "plain": "Olatorepatide is a weekly weight-loss injection that copies the gut hormones GLP-1 and GIP, like tirzepatide. Its first large trial in China reported in October 2026, and Regeneron is testing it in other countries.",
   "scientific": "Olatorepatide (HS-20094) is a GLP-1 and GIP receptor dual agonist that its developer describes as dual-biased. Hansoh reported the LIGHTEN phase 3 results under both treatment-regimen and efficacy estimands. Regeneron licensed rights outside mainland China, Hong Kong and Macau in June 2025 and has registered phase 2 and phase 3 trials, including one in hidradenitis suppurativa.",
   "entry": "olatorepatide",
   "sources": {
    "hansoh": {
     "kind": "sponsor",
     "label": "Hansoh Pharma (EQS release): 19.3% weight loss at week 48, phase 3 data of olatorepatide presented at EASD (October 2, 2026)",
     "url": "https://www.webdisclosure.com/press-release/193-weight-loss-at-week-48-phase-data-of-olatorepatide-hansohs-dualbiased-glp1gip-agonist-presented-at-easd-DXlO26IS9vw",
     "date": "2026-10-02",
     "read": "2026-10-28"
    },
    "regn": {
     "kind": "sponsor",
     "label": "Regeneron: in-licensing of HS-20094 from Hansoh (June 2, 2025)",
     "url": "https://investor.regeneron.com/node/31066/pdf",
     "date": "2025-06-02",
     "read": "2026-10-28"
    },
    "lighten_reg": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06839664 (A Study of HS-20094 in Chinese Adults With Overweight or Obesity)",
     "url": "https://clinicaltrials.gov/study/NCT06839664",
     "nct": "NCT06839664",
     "read": "2026-10-28"
    },
    "rise1": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07896265 (RISE-1)",
     "url": "https://clinicaltrials.gov/study/NCT07896265",
     "nct": "NCT07896265",
     "read": "2026-10-28"
    },
    "us2": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07431086 (Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US)",
     "url": "https://clinicaltrials.gov/study/NCT07431086",
     "nct": "NCT07431086",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-10-02",
    "what": "LIGHTEN phase 3 results presented",
    "source": "hansoh"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "hansoh",
    "regn",
    "rise1"
   ],
   "class": "Dual-biased GLP-1 and GIP receptor agonist"
  },
  {
   "id": "ribupatide",
   "name": "Ribupatide",
   "aliases": [
    "HRS9531"
   ],
   "sponsor": "Jiangsu Hengrui (trials registered by Fujian Shengdi Pharmaceutical)",
   "target": "GLP-1 and GIP receptors",
   "mechanism": "Weekly incretin dual agonist; an oral tablet form is also in phase 3",
   "areas": [
    "obesity-diabetes"
   ],
   "indications": [
    "Obesity",
    "Type 2 diabetes",
    "Obstructive sleep apnoea",
    "Atherosclerotic cardiovascular disease"
   ],
   "phase": "phase 3",
   "phase_note": "Phase 3 programme in China, including an oral tablet trial started July 2026",
   "phase_sources": [
    "p3obs",
    "osa"
   ],
   "ncts": [
    "NCT06396429",
    "NCT06994650",
    "NCT07670884"
   ],
   "last_readout": {
    "date": "2026-09-20",
    "result": "First-in-human study (Diabetes Obes Metab): after four weekly doses, weight fell 6.7% to 9.6% against 1.4% on placebo",
    "source": "fih"
   },
   "next_milestone": {
    "what": "Primary completion of the phase 3 trial in sleep apnoea with obesity",
    "expected": "2026-12",
    "source": "osa"
   },
   "plain": "Ribupatide is a weekly injection from China that copies the hormones GLP-1 and GIP to help with weight and blood sugar. A tablet form is also being tested.",
   "scientific": "Ribupatide (HRS9531) is a dual GLP-1/GIP receptor agonist whose mean half-life in its first-in-human study was 7 to 8 days. A placebo-controlled phase 3 obesity trial in China reached primary completion in July 2025. Further phase 3 trials cover sleep apnoea and an oral tablet formulation.",
   "entry": "hrs9531",
   "sources": {
    "fih": {
     "kind": "paper",
     "label": "He K, et al. Preclinical and First-In-Human Evaluation of Ribupatide (HRS9531), a Dual GLP-1/GIP Receptor Agonist. Diabetes Obes Metab 2026",
     "pmid": "42764407",
     "url": "https://pubmed.ncbi.nlm.nih.gov/42764407/",
     "read": "2026-10-28"
    },
    "p3obs": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06396429 (To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese)",
     "url": "https://clinicaltrials.gov/study/NCT06396429",
     "nct": "NCT06396429",
     "read": "2026-10-28"
    },
    "osa": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06994650 (A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy)",
     "url": "https://clinicaltrials.gov/study/NCT06994650",
     "nct": "NCT06994650",
     "read": "2026-10-28"
    },
    "oral": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07670884 (A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects)",
     "url": "https://clinicaltrials.gov/study/NCT07670884",
     "nct": "NCT07670884",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-07-24",
    "what": "Oral tablet phase 3 started",
    "source": "oral"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "fih",
    "p3obs",
    "oral"
   ],
   "class": "GLP-1 and GIP receptor dual agonist"
  },
  {
   "id": "vk2735",
   "name": "VK2735",
   "aliases": [],
   "sponsor": "Viking Therapeutics",
   "target": "GLP-1 and GIP receptors",
   "mechanism": "Incretin dual agonist given as a weekly injection or a daily tablet",
   "areas": [
    "obesity-diabetes"
   ],
   "indications": [
    "Obesity",
    "Obesity with type 2 diabetes"
   ],
   "phase": "phase 3",
   "phase_note": "VANQUISH (injection) phase 3 enrolled; Viking says the SUNRISE (oral) phase 3 trials began in October 2026",
   "phase_sources": [
    "v1",
    "sunrise",
    "q3"
   ],
   "ncts": [
    "NCT07104500",
    "NCT07104383",
    "NCT07868835"
   ],
   "last_readout": {
    "date": "2026-09-22",
    "result": "Maintenance study (Viking topline, not yet published): 16% to 19% weight loss after 21 weeks of weekly injections; monthly maintenance doses kept 82% to 90% of it at week 33, against 61% on placebo",
    "source": "q3"
   },
   "next_milestone": {
    "what": "Primary completion of VANQUISH 1",
    "expected": "2027-07-01",
    "source": "v1"
   },
   "plain": "VK2735 is a weight-loss medicine that copies the gut hormones GLP-1 and GIP. It is being tested as a weekly injection and as a daily pill.",
   "scientific": "VK2735 is a dual agonist of the GLP-1 and GIP receptors. In the 13-week VENTURE phase 2 trial all subcutaneous doses reduced body weight, with mainly gastrointestinal adverse events that became less frequent after titration. VANQUISH 1 and 2 test the injection in phase 3; SUNRISE 1 tests the tablet.",
   "entry": "vk2735",
   "sources": {
    "venture": {
     "kind": "paper",
     "label": "Bays HE, et al. Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2 VENTURE. Obesity 2026",
     "pmid": "41508550",
     "url": "https://pubmed.ncbi.nlm.nih.gov/41508550/",
     "read": "2026-10-28"
    },
    "v1": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07104500 (VANQUISH 1)",
     "url": "https://clinicaltrials.gov/study/NCT07104500",
     "nct": "NCT07104500",
     "read": "2026-10-28"
    },
    "v2": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07104383 (VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2))",
     "url": "https://clinicaltrials.gov/study/NCT07104383",
     "nct": "NCT07104383",
     "read": "2026-10-28"
    },
    "sunrise": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07868835 (Oral VK2735 for Weight Management Phase 3 (SUNRISE 1))",
     "url": "https://clinicaltrials.gov/study/NCT07868835",
     "nct": "NCT07868835",
     "read": "2026-10-28"
    },
    "q3": {
     "kind": "filing",
     "label": "Viking Therapeutics: third quarter 2026 financial results and corporate update (Form 8-K exhibit, October 28, 2026)",
     "url": "https://www.sec.gov/Archives/edgar/data/0001607678/000119312526436145/vktx-ex99_1.htm",
     "date": "2026-10-28",
     "read": "2026-11-03"
    }
   },
   "changed": {
    "date": "2026-10-28",
    "what": "Viking reports the oral SUNRISE phase 3 trials under way",
    "source": "q3"
   },
   "last_checked": "2026-11-03",
   "explainer_sources": [
    "venture",
    "v1",
    "sunrise"
   ],
   "class": "GLP-1 and GIP receptor dual agonist"
  },
  {
   "id": "ubt251",
   "name": "UBT251",
   "aliases": [],
   "sponsor": "The United Bio-Technology (Hengqin) in China; Novo Nordisk runs trials outside China",
   "target": "GLP-1, GIP and glucagon receptors",
   "mechanism": "A weekly triple agonist in the retatrutide class",
   "areas": [
    "obesity-diabetes"
   ],
   "indications": [
    "Obesity",
    "Type 2 diabetes",
    "Obstructive sleep apnoea"
   ],
   "phase": "phase 3",
   "phase_note": "Phase 3 in China (UNIGUIDE, UNISHAPE); Novo Nordisk phase 2 elsewhere",
   "phase_sources": [
    "uniguide1",
    "novo2"
   ],
   "ncts": [
    "NCT07659574",
    "NCT07648225",
    "NCT07668388"
   ],
   "last_readout": {
    "date": "2026-10-08",
    "result": "Phase 2 in obesity (Cell Metab): weight fell 13.6% to 19.7% against 2.0% on placebo at 24 weeks",
    "source": "p2obs"
   },
   "next_milestone": {
    "what": "Primary completion of UNIGUIDE-1 in type 2 diabetes",
    "expected": "2027-09-24",
    "source": "uniguide1"
   },
   "plain": "UBT251 copies three hormones at once, like retatrutide. A Chinese company is testing it in large trials, and Novo Nordisk is testing it elsewhere. Mid-size trials showed large weight loss in six months.",
   "scientific": "UBT251 is a triple agonist of the GLP-1, GIP and glucagon receptors. Two 24-week phase 2 trials published in Cell Metabolism in October 2026 reported weight reduction against placebo in obesity and HbA1c reduction against placebo and semaglutide in type 2 diabetes. Phase 3 trials run in China and a Novo Nordisk phase 2 elsewhere.",
   "entry": "ubt251",
   "sources": {
    "p2obs": {
     "kind": "paper",
     "label": "Zhou Z, et al. UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with overweight or obesity: a phase 2 trial. Cell Metab 2026",
     "pmid": "42843337",
     "url": "https://pubmed.ncbi.nlm.nih.gov/42843337/",
     "read": "2026-10-28"
    },
    "p2t2d": {
     "kind": "paper",
     "label": "Zhou Z, et al. UBT251 in adults with type 2 diabetes: a multicenter, randomized phase 2 trial. Cell Metab 2026",
     "pmid": "42933400",
     "url": "https://pubmed.ncbi.nlm.nih.gov/42933400/",
     "read": "2026-10-28"
    },
    "uniguide1": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07659574 (UNIGUIDE-1)",
     "url": "https://clinicaltrials.gov/study/NCT07659574",
     "nct": "NCT07659574",
     "read": "2026-10-28"
    },
    "obs3": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07648225 (UBT251 Injection Phase Ⅲ Study (Overweight or Obesity))",
     "url": "https://clinicaltrials.gov/study/NCT07648225",
     "nct": "NCT07648225",
     "read": "2026-10-28"
    },
    "novo2": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07668388 (A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes)",
     "url": "https://clinicaltrials.gov/study/NCT07668388",
     "nct": "NCT07668388",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-10-08",
    "what": "Phase 2 obesity trial published",
    "source": "p2obs"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "p2obs",
    "p2t2d",
    "novo2"
   ],
   "class": "GLP-1, GIP and glucagon receptor triple agonist"
  },
  {
   "id": "lenbelintide",
   "name": "Lenbelintide",
   "aliases": [
    "AZD6234"
   ],
   "sponsor": "AstraZeneca",
   "target": "Amylin receptors",
   "mechanism": "Weekly amylin mimic, tested alone and as an add-on to GLP-1 drugs",
   "areas": [
    "obesity-diabetes"
   ],
   "indications": [
    "Obesity",
    "Type 2 diabetes",
    "Add-on to incretin therapy"
   ],
   "phase": "phase 3",
   "phase_note": "SELENE phase 3 programme started August 2026",
   "phase_sources": [
    "selene1"
   ],
   "ncts": [
    "NCT07784725",
    "NCT07776509",
    "NCT06851858"
   ],
   "last_readout": {
    "date": "2026-05-26",
    "result": "Phase 2 ARAY reached primary completion; no results were posted on the registry when read",
    "source": "aray"
   },
   "next_milestone": {
    "what": "Primary completion of SELENE 1",
    "expected": "2028-08-11",
    "source": "selene1"
   },
   "plain": "Lenbelintide is AstraZeneca's weekly copy of the fullness hormone amylin. It is being tested on its own and on top of GLP-1 medicines.",
   "scientific": "Lenbelintide (AZD6234) is a long-acting amylin analogue. SELENE 1 tests it alone in obesity without diabetes, and SELENE 3 tests it as an adjunct to incretin-based therapy. Its phase 2 trial reached primary completion in May 2026.",
   "entry": "azd6234",
   "sources": {
    "review": {
     "kind": "paper",
     "label": "Alhazmi A, et al. Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials. Diabetes Obes Metab 2026",
     "pmid": "42452898",
     "url": "https://pubmed.ncbi.nlm.nih.gov/42452898/",
     "read": "2026-10-28"
    },
    "selene1": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07784725 (SELENE 1)",
     "url": "https://clinicaltrials.gov/study/NCT07784725",
     "nct": "NCT07784725",
     "read": "2026-10-28"
    },
    "selene3": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07776509 (SELENE 3)",
     "url": "https://clinicaltrials.gov/study/NCT07776509",
     "nct": "NCT07776509",
     "read": "2026-10-28"
    },
    "aray": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06851858 (ARAY)",
     "url": "https://clinicaltrials.gov/study/NCT06851858",
     "nct": "NCT06851858",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-08-19",
    "what": "SELENE 1 phase 3 started",
    "source": "selene1"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "review",
    "selene1",
    "selene3",
    "aray"
   ],
   "class": "Long-acting selective amylin receptor agonist"
  },
  {
   "id": "pemvidutide",
   "name": "Pemvidutide",
   "aliases": [
    "ALT-801"
   ],
   "sponsor": "Altimmune",
   "target": "GLP-1 and glucagon receptors",
   "mechanism": "Balanced dual agonist aimed at liver fat and inflammation",
   "areas": [
    "cardiometabolic",
    "gi"
   ],
   "indications": [
    "MASH (fatty liver disease with inflammation)",
    "Alcohol-associated liver disease (phase 2)"
   ],
   "phase": "phase 3",
   "phase_note": "Phase 3 PERFORMA in MASH started July 30, 2026",
   "phase_sources": [
    "performa"
   ],
   "ncts": [
    "NCT05989711",
    "NCT07795164",
    "NCT07009860"
   ],
   "last_readout": {
    "date": "2025-11-11",
    "result": "IMPACT phase 2b (Lancet): MASH resolution in 58% and 52% against 20% on placebo at 24 weeks; the fibrosis endpoint was not met",
    "source": "impact"
   },
   "next_milestone": {
    "what": "Primary completion of RESTORE, the phase 2 trial in alcohol-associated liver disease",
    "expected": "2027-09-30",
    "source": "restore"
   },
   "plain": "Pemvidutide is a weekly injection being tested for a serious kind of fatty liver disease called MASH. In its main trial it cleared the liver inflammation in about half of people, but did not yet improve scarring.",
   "scientific": "Pemvidutide is a GLP-1 and glucagon receptor dual agonist. In IMPACT, a phase 2b trial in biopsy-confirmed MASH with F2-F3 fibrosis, it met the MASH-resolution endpoint at 24 weeks but not the fibrosis-improvement endpoint. The phase 3 PERFORMA trial began in July 2026, and RESTORE studies alcohol-associated liver disease.",
   "entry": "pemvidutide",
   "sources": {
    "impact": {
     "kind": "paper",
     "label": "Noureddin M, et al. Weekly pemvidutide versus placebo for MASH (IMPACT): 24-week results of a phase 2b study. Lancet 2025;406:2644-2655",
     "pmid": "41237796",
     "url": "https://pubmed.ncbi.nlm.nih.gov/41237796/",
     "read": "2026-10-28"
    },
    "performa": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07795164 (PERFORMA)",
     "url": "https://clinicaltrials.gov/study/NCT07795164",
     "nct": "NCT07795164",
     "read": "2026-10-28"
    },
    "restore": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07009860 (RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD))",
     "url": "https://clinicaltrials.gov/study/NCT07009860",
     "nct": "NCT07009860",
     "read": "2026-10-28"
    },
    "impact_reg": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT05989711 (IMPACT)",
     "url": "https://clinicaltrials.gov/study/NCT05989711",
     "nct": "NCT05989711",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-07-30",
    "what": "Phase 3 PERFORMA started",
    "source": "performa"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "impact",
    "performa",
    "restore"
   ],
   "class": "GLP-1 and glucagon receptor dual agonist"
  },
  {
   "id": "glepaglutide",
   "name": "Glepaglutide",
   "aliases": [
    "ZP1848"
   ],
   "sponsor": "Zealand Pharma",
   "target": "GLP-2 receptor",
   "mechanism": "Stimulates growth and absorption in the remaining bowel",
   "areas": [
    "gi",
    "rare-disease"
   ],
   "indications": [
    "Short bowel syndrome with intestinal failure"
   ],
   "phase": "phase 3",
   "phase_note": "A new confirmatory phase 3 (EASE SBS 5) began February 2026",
   "phase_sources": [
    "ease5"
   ],
   "ncts": [
    "NCT03690206",
    "NCT07197944",
    "NCT07228403"
   ],
   "last_readout": {
    "date": "2024-12-19",
    "result": "EASE SBS 1 (Gastroenterology): twice-weekly dosing cut parenteral support more than placebo; once-weekly dosing did not separate from placebo",
    "source": "ease1"
   },
   "next_milestone": {
    "what": "Primary completion of EASE SBS 5",
    "expected": "2028-10-23",
    "source": "ease5"
   },
   "plain": "People who have lost much of their small intestine often need nutrition through a drip. Glepaglutide copies a gut hormone, GLP-2, that helps the remaining bowel absorb more. It is in a new large trial to confirm earlier results.",
   "scientific": "Glepaglutide is a long-acting GLP-2 analogue designed for a ready-to-use liquid formulation. In EASE SBS 1 the twice-weekly regimen reduced parenteral support more than placebo; the once-weekly regimen did not differ significantly. EASE SBS 5 is a new placebo-controlled phase 3 of the twice-weekly regimen.",
   "entry": "glepaglutide",
   "sources": {
    "ease1": {
     "kind": "paper",
     "label": "Jeppesen PB, et al. Glepaglutide, a Long-Acting GLP-2 Analogue, Reduces Parenteral Support in Patients With Short Bowel Syndrome: A Phase 3 Trial. Gastroenterology 2024",
     "pmid": "39708985",
     "url": "https://pubmed.ncbi.nlm.nih.gov/39708985/",
     "read": "2026-10-28"
    },
    "ease5": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07197944 (EASE SBS 5)",
     "url": "https://clinicaltrials.gov/study/NCT07197944",
     "nct": "NCT07197944",
     "read": "2026-10-28"
    },
    "ease1_reg": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT03690206 (EASE SBS 1)",
     "url": "https://clinicaltrials.gov/study/NCT03690206",
     "nct": "NCT03690206",
     "read": "2026-10-28"
    },
    "ext": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07228403 (EASE SBS 6)",
     "url": "https://clinicaltrials.gov/study/NCT07228403",
     "nct": "NCT07228403",
     "read": "2026-10-28"
    },
    "chem": {
     "kind": "paper",
     "label": "Larsen BD, et al. Creating Glepaglutide, the First Long-Acting GLP-2 Analogue to Enable a Ready-to-Use Injection. J Med Chem 2025",
     "pmid": "39851172",
     "url": "https://pubmed.ncbi.nlm.nih.gov/39851172/",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-02-11",
    "what": "EASE SBS 5 phase 3 started",
    "source": "ease5"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "chem",
    "ease1",
    "ease5"
   ],
   "class": "Long-acting GLP-2 analogue"
  },
  {
   "id": "apraglutide",
   "name": "Apraglutide",
   "aliases": [
    "FE 203799"
   ],
   "sponsor": "VectivBio",
   "target": "GLP-2 receptor",
   "mechanism": "Weekly GLP-2 mimic for bowel adaptation",
   "areas": [
    "gi",
    "rare-disease"
   ],
   "indications": [
    "Short bowel syndrome with intestinal failure"
   ],
   "phase": "phase 3",
   "phase_note": "STARS-2 phase 3 recruiting since August 2026",
   "phase_sources": [
    "stars2"
   ],
   "ncts": [
    "NCT04627025",
    "NCT07742735"
   ],
   "last_readout": {
    "date": "2026-09-03",
    "result": "STARS (Clin Gastroenterol Hepatol): weekly apraglutide significantly reduced parenteral support volume; the 48-week secondary comparisons were not significant",
    "source": "stars"
   },
   "next_milestone": {
    "what": "Primary completion of STARS-2",
    "expected": "2028-10",
    "source": "stars2"
   },
   "plain": "Apraglutide is a once-a-week version of the gut hormone GLP-2 for people with short bowel syndrome. It helps the remaining gut absorb more, so they need less drip feeding.",
   "scientific": "Apraglutide is a once-weekly GLP-2 analogue. In the STARS phase 3 trial it significantly reduced parenteral support requirements against placebo; at week 48 the days-off and enteral-autonomy comparisons were not statistically significant. STARS-2 is a second placebo-controlled phase 3.",
   "entry": "apraglutide",
   "sources": {
    "stars": {
     "kind": "paper",
     "label": "Joly F, et al. STARS Phase 3 Trial: Once-Weekly Apraglutide Reduces Parenteral Support in Short Bowel Syndrome-Intestinal Failure. Clin Gastroenterol Hepatol 2026",
     "pmid": "42692160",
     "url": "https://pubmed.ncbi.nlm.nih.gov/42692160/",
     "read": "2026-10-28"
    },
    "stars2": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07742735 (STARS-2)",
     "url": "https://clinicaltrials.gov/study/NCT07742735",
     "nct": "NCT07742735",
     "read": "2026-10-28"
    },
    "stars_reg": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT04627025 (STARS)",
     "url": "https://clinicaltrials.gov/study/NCT04627025",
     "nct": "NCT04627025",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-09-03",
    "what": "STARS phase 3 published",
    "source": "stars"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "stars",
    "stars2"
   ],
   "class": "Once-weekly GLP-2 analogue"
  },
  {
   "id": "avexitide",
   "name": "Avexitide",
   "aliases": [
    "exendin (9-39)"
   ],
   "sponsor": "Amylyx Pharmaceuticals",
   "target": "GLP-1 receptor",
   "mechanism": "Blocks the GLP-1 receptor to stop the insulin surges that cause low blood sugar after gastric bypass",
   "areas": [
    "rare-disease",
    "endocrine"
   ],
   "indications": [
    "Post-bariatric hypoglycaemia"
   ],
   "phase": "phase 3",
   "phase_note": "Phase 3 LUCIDITY positive (August 18, 2026); Amylyx plans to submit an NDA by the end of 2026",
   "phase_sources": [
    "lucidity_reg",
    "amylyx"
   ],
   "ncts": [
    "NCT06747468"
   ],
   "last_readout": {
    "date": "2026-08-18",
    "result": "LUCIDITY: 55% fewer level 2 and 3 hypoglycaemia events than placebo through week 16 (company release)",
    "source": "amylyx"
   },
   "next_milestone": {
    "what": "Planned New Drug Application submission",
    "expected": "2026-12",
    "source": "amylyx"
   },
   "plain": "After some weight-loss surgeries, the body can release too much insulin after a meal and blood sugar can crash. Avexitide blocks the GLP-1 signal that drives that insulin rush. Its main trial worked, and the company plans to apply for approval by the end of 2026.",
   "scientific": "Avexitide is a GLP-1 receptor antagonist peptide (exendin 9-39). In post-bariatric hypoglycaemia, blocking the receptor blunts the exaggerated insulin response after meals. The phase 3 LUCIDITY trial met its primary endpoint on the rate of level 2 and level 3 hypoglycaemic events through week 16, and a phase 2b study was published in 2026.",
   "entry": "avexitide",
   "sources": {
    "amylyx": {
     "kind": "sponsor",
     "label": "Amylyx Pharmaceuticals, Form 8-K exhibit 99.1: LUCIDITY phase 3 topline results (August 18, 2026)",
     "url": "https://www.sec.gov/Archives/edgar/data/0001658551/000119312526354716/d180533dex991.htm",
     "date": "2026-08-18",
     "read": "2026-10-28"
    },
    "lucidity_reg": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06747468 (LUCIDITY)",
     "url": "https://clinicaltrials.gov/study/NCT06747468",
     "nct": "NCT06747468",
     "read": "2026-10-28"
    },
    "p2b": {
     "kind": "paper",
     "label": "Craig C, et al. Efficacy and safety of avexitide for hypoglycemia following bariatric and other upper gastrointestinal surgeries: a phase 2b study",
     "pmid": "42744082",
     "url": "https://pubmed.ncbi.nlm.nih.gov/42744082/",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-08-18",
    "what": "LUCIDITY phase 3 positive; NDA planned by end of 2026",
    "source": "amylyx"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "amylyx",
    "lucidity_reg",
    "p2b"
   ],
   "class": "GLP-1 receptor antagonist peptide"
  },
  {
   "id": "eneboparatide",
   "name": "Eneboparatide",
   "aliases": [
    "AZP-3601"
   ],
   "sponsor": "AstraZeneca (Alexion)",
   "target": "PTH1 receptor",
   "mechanism": "Long-acting PTH-receptor agonist designed to hold blood calcium steady",
   "areas": [
    "endocrine",
    "rare-disease"
   ],
   "indications": [
    "Chronic hypoparathyroidism"
   ],
   "phase": "phase 3",
   "phase_note": "Phase 3 CALYPSO positive; two-year extension ongoing",
   "phase_sources": [
    "calypso_reg",
    "az"
   ],
   "ncts": [
    "NCT05778071"
   ],
   "last_readout": {
    "date": "2026-05-12",
    "result": "CALYPSO week 24: 31.1% normalised serum calcium off active vitamin D and with little calcium, against 5.9% on placebo (company release)",
    "source": "az"
   },
   "next_milestone": {
    "what": "Study completion of CALYPSO, including the long-term period (registry estimate)",
    "expected": "2027-06-16",
    "source": "calypso_reg"
   },
   "plain": "When the parathyroid glands stop working, calcium in the blood drops and people need many pills a day. Eneboparatide is a daily injection that copies parathyroid hormone to keep calcium normal. In its main trial about a third of patients could stop their supplements.",
   "scientific": "Eneboparatide is a parathyroid hormone receptor agonist developed as a long-acting PTH analogue. CALYPSO's composite primary endpoint required normal albumin-adjusted serum calcium without active vitamin D and with little oral calcium at week 24; it was met, and urinary calcium normalised more often than on placebo in those hypercalciuric at baseline, according to the company. A two-year extension is ongoing.",
   "entry": "eneboparatide",
   "sources": {
    "az": {
     "kind": "sponsor",
     "label": "AstraZeneca: eneboparatide normalised serum calcium and achieved independence from supplements in 31.1% of adults with hypoparathyroidism at week 24 in CALYPSO (May 12, 2026)",
     "url": "https://www.astrazeneca.com/media-centre/press-releases/2026/eneboparatide-normalised-serum-calcium-and-achieved-independence-from-supplements-in-31-1-percent-of-adults-with-HypoPT-in-CALYPSO-Phase-iii-trial.html",
     "date": "2026-05-12",
     "read": "2026-10-28"
    },
    "calypso_reg": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT05778071 (CALYPSO)",
     "url": "https://clinicaltrials.gov/study/NCT05778071",
     "nct": "NCT05778071",
     "read": "2026-10-28"
    },
    "review": {
     "kind": "paper",
     "label": "Brandi ML, et al. Hypoparathyroidism: translating science from the laboratory to the clinic. Lancet Diabetes Endocrinol 2026",
     "pmid": "42705258",
     "url": "https://pubmed.ncbi.nlm.nih.gov/42705258/",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-05-12",
    "what": "CALYPSO 24-week results presented",
    "source": "az"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "az",
    "review",
    "calypso_reg"
   ],
   "class": "Parathyroid hormone receptor agonist peptide"
  },
  {
   "id": "vosoritide-hch",
   "name": "Vosoritide (hypochondroplasia)",
   "aliases": [
    "Voxzogo",
    "BMN 111"
   ],
   "sponsor": "BioMarin",
   "target": "NPR-B",
   "mechanism": "Counteracts the FGFR3 growth-plate brake shared by achondroplasia and hypochondroplasia",
   "areas": [
    "rare-disease",
    "endocrine"
   ],
   "indications": [
    "Hypochondroplasia (phase 3; new indication)",
    "Achondroplasia (approved 2021)"
   ],
   "phase": "phase 3",
   "phase_note": "New indication in phase 3; vosoritide itself has been approved for achondroplasia since 2021",
   "phase_sources": [
    "canopy"
   ],
   "ncts": [
    "NCT06455059",
    "NCT07073014",
    "NCT07126262"
   ],
   "last_readout": {
    "date": "2026-09-09",
    "result": "CANOPY-HCH-3 (NEJM Evidence): yearly growth 2.33 cm faster than placebo after 52 weeks in 81 children",
    "source": "hch3"
   },
   "next_milestone": {
    "what": "Primary completion of the phase 2 trial in children under 3 years",
    "expected": "2028-06-30",
    "source": "infant"
   },
   "plain": "Hypochondroplasia is a milder cousin of achondroplasia caused by changes in the same gene. Vosoritide, a daily injection already used for achondroplasia, helped children with hypochondroplasia grow faster in a one-year trial. It is not approved for this condition.",
   "scientific": "Vosoritide is a C-type natriuretic peptide analogue that works against overactive FGFR3 signalling at the growth plate. In the CANOPY-HCH-3 phase 3 trial annualised growth velocity rose by 2.33 cm a year more than on placebo at 52 weeks, with no grade 3 or higher adverse events. Effects on adult height are unknown; an open-label extension runs to 2044.",
   "entry": "vosoritide",
   "sources": {
    "hch3": {
     "kind": "paper",
     "label": "Dauber A, et al. A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia. NEJM Evid 2026",
     "pmid": "42713641",
     "url": "https://pubmed.ncbi.nlm.nih.gov/42713641/",
     "read": "2026-10-28"
    },
    "canopy": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06455059 (CANOPY-HCH-3)",
     "url": "https://clinicaltrials.gov/study/NCT06455059",
     "nct": "NCT06455059",
     "read": "2026-10-28"
    },
    "ext": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07073014 (CANOPY-HCH-EXT)",
     "url": "https://clinicaltrials.gov/study/NCT07073014",
     "nct": "NCT07073014",
     "read": "2026-10-28"
    },
    "infant": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07126262 (A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months)",
     "url": "https://clinicaltrials.gov/study/NCT07126262",
     "nct": "NCT07126262",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-09-09",
    "what": "Phase 3 published in NEJM Evidence",
    "source": "hch3"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "hch3",
    "canopy",
    "ext"
   ],
   "class": "C-type natriuretic peptide analogue"
  },
  {
   "id": "afamelanotide-vitiligo",
   "name": "Afamelanotide (vitiligo)",
   "aliases": [
    "Scenesse",
    "CUV105"
   ],
   "sponsor": "Clinuvel",
   "target": "MC1R",
   "mechanism": "Stimulates melanocytes to make pigment, alongside narrow-band UVB light",
   "areas": [
    "dermatology"
   ],
   "indications": [
    "Vitiligo (phase 3; new indication)",
    "Erythropoietic protoporphyria (approved 2019)"
   ],
   "phase": "phase 3",
   "phase_note": "Phase 3 CUV105 with narrow-band UVB; the drug is already approved for erythropoietic protoporphyria",
   "phase_sources": [
    "cuv105"
   ],
   "ncts": [
    "NCT06109649"
   ],
   "last_readout": {
    "date": "2015",
    "result": "Earlier randomised trial (JAMA Dermatology): afamelanotide plus NB-UVB gave faster repigmentation than NB-UVB alone",
    "source": "p2"
   },
   "next_milestone": {
    "what": "CUV105 results; the registered primary completion estimate (December 2025) has passed without an update",
    "expected": "2025-12",
    "source": "cuv105"
   },
   "plain": "Vitiligo causes white patches where the skin's pigment cells have stopped working. Afamelanotide copies a natural tanning hormone. Combined with a special light treatment, it helped colour come back faster in an earlier trial.",
   "scientific": "Afamelanotide is a melanocortin-1 receptor agonist that stimulates melanin production. In a randomised trial, afamelanotide plus narrow-band UVB gave faster and greater repigmentation than narrow-band UVB alone, most clearly in darker skin types. The phase 3 CUV105 trial compares the same combination; its registered completion estimate has passed without an update.",
   "entry": "afamelanotide",
   "sources": {
    "p2": {
     "kind": "paper",
     "label": "Lim HW, et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol 2015",
     "pmid": "25230094",
     "url": "https://pubmed.ncbi.nlm.nih.gov/25230094/",
     "read": "2026-10-28"
    },
    "cuv105": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06109649 (A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo)",
     "url": "https://clinicaltrials.gov/study/NCT06109649",
     "nct": "NCT06109649",
     "read": "2026-10-28"
    }
   },
   "changed": null,
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "p2",
    "cuv105"
   ],
   "class": "Alpha-MSH analogue (melanocortin-1 receptor agonist)"
  },
  {
   "id": "ryz101",
   "name": "Actinium Ac 225 dotatate",
   "aliases": [
    "RYZ101",
    "225Ac-DOTATATE"
   ],
   "sponsor": "RayzeBio",
   "target": "Somatostatin receptor 2",
   "mechanism": "Delivers an alpha-emitting atom, which causes dense, short-range DNA damage, to SSTR2-positive tumours",
   "areas": [
    "oncology"
   ],
   "indications": [
    "Neuroendocrine tumours after lutetium-177 therapy",
    "Small-cell lung cancer, breast cancer, meningioma (early trials)"
   ],
   "phase": "phase 3",
   "phase_note": "ACTION-1 phase 1b/3",
   "phase_sources": [
    "action1"
   ],
   "ncts": [
    "NCT05477576"
   ],
   "last_readout": {
    "date": "2026-08-03",
    "result": "ACTION-1 phase 1b dosimetry (J Nucl Med): favourable tumour-to-normal-tissue absorbed dose ratios",
    "source": "dosim"
   },
   "next_milestone": {
    "what": "Primary completion of ACTION-1",
    "expected": "2026-12",
    "source": "action1"
   },
   "plain": "This is a radioactive cancer drug for neuroendocrine tumours that keep growing after an older radioactive treatment. It uses actinium, which gives off very strong radiation over a tiny distance.",
   "scientific": "RYZ101 is DOTATATE, a somatostatin analogue, carrying actinium-225, an alpha emitter whose particles deliver high energy over a short path and cause largely irreparable double-strand DNA breaks. ACTION-1 randomises patients with SSTR-positive GEP-NETs that progressed after lutetium-177 somatostatin-analogue therapy to RYZ101 or standard care. Dosimetry from its phase 1b part found a favourable tumour-to-normal-tissue absorbed dose ratio.",
   "entry": null,
   "sources": {
    "dosim": {
     "kind": "paper",
     "label": "Sgouros G, et al. Dosimetry Results from the Phase 1b/3 ACTION-1 Trial of [225Ac]Ac-DOTATATE (RYZ101). J Nucl Med 2026;67:1239-1246",
     "pmid": "42242867",
     "url": "https://pubmed.ncbi.nlm.nih.gov/42242867/",
     "read": "2026-10-28"
    },
    "action1": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT05477576 (ACTION-1)",
     "url": "https://clinicaltrials.gov/study/NCT05477576",
     "nct": "NCT05477576",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-08-03",
    "what": "Phase 1b dosimetry published",
    "source": "dosim"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "dosim",
    "action1"
   ],
   "class": "Alpha-emitting somatostatin-analogue radioligand"
  },
  {
   "id": "azd2265",
   "name": "Actinium Ac 225 zadavotide guraxetan",
   "aliases": [
    "AZD2265",
    "FPI-2265",
    "225Ac-PSMA-I&T"
   ],
   "sponsor": "AstraZeneca",
   "target": "PSMA",
   "mechanism": "Delivers actinium-225 to PSMA-positive prostate cancer",
   "areas": [
    "oncology"
   ],
   "indications": [
    "Metastatic castration-resistant prostate cancer after lutetium-177 PSMA therapy"
   ],
   "phase": "phase 3",
   "phase_note": "VECTRA-01 phase 3 started May 2026",
   "phase_sources": [
    "vectra"
   ],
   "ncts": [
    "NCT07611110"
   ],
   "last_readout": null,
   "next_milestone": {
    "what": "Primary completion of VECTRA-01",
    "expected": "2029-06-04",
    "source": "vectra"
   },
   "plain": "This drug carries a strong but short-range radioactive atom, actinium, to prostate cancer cells that display PSMA. It is being tested in men whose cancer kept growing after an earlier PSMA radiation drug.",
   "scientific": "AZD2265 (FPI-2265) is 225Ac-PSMA-I&T. VECTRA-01 randomises men with PSMA-positive metastatic castration-resistant prostate cancer previously treated with a beta-emitting PSMA radioconjugate, a taxane and an androgen-pathway inhibitor to AZD2265 or standard therapy, with radiographic progression-free survival and overall survival as primary endpoints.",
   "entry": "zadavotide-guraxetan",
   "sources": {
    "vectra": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07611110 (VECTRA-01)",
     "url": "https://clinicaltrials.gov/study/NCT07611110",
     "nct": "NCT07611110",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-05-04",
    "what": "VECTRA-01 phase 3 started",
    "source": "vectra"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "vectra"
   ],
   "class": "Alpha-emitting PSMA radioligand"
  },
  {
   "id": "lutetium-psma-it",
   "name": "Lutetium Lu 177 PSMA-I&T",
   "aliases": [
    "177Lu-PSMA-I&T",
    "ECLIPSE"
   ],
   "sponsor": "Curium",
   "target": "PSMA",
   "mechanism": "Delivers lutetium-177 to PSMA-positive prostate cancer",
   "areas": [
    "oncology"
   ],
   "indications": [
    "Metastatic castration-resistant prostate cancer after an androgen-pathway inhibitor"
   ],
   "phase": "phase 3",
   "phase_note": "ECLIPSE phase 3 met its primary endpoint (November 2024); no filing date in the company's release",
   "phase_sources": [
    "eclipse_reg",
    "curium"
   ],
   "ncts": [
    "NCT05204927"
   ],
   "last_readout": {
    "date": "2024-11-13",
    "result": "ECLIPSE met its primary endpoint: longer radiographic progression-free survival than switching hormone therapy (company release)",
    "source": "curium"
   },
   "next_milestone": {
    "what": "Regulatory submission; Curium said it would develop a submission plan with FDA as data mature, without a date",
    "expected": null,
    "source": "curium"
   },
   "plain": "This is another radioactive drug aimed at the PSMA marker on prostate cancer cells, from a different company than Pluvicto. Its main trial slowed the cancer more than switching to a different hormone pill.",
   "scientific": "177Lu-PSMA-I&T is a lutetium-177-labelled PSMA ligand. ECLIPSE randomised patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with an androgen-pathway inhibitor to 177Lu-PSMA-I&T or a change of hormone therapy, and the company reported that it met its radiographic progression-free survival endpoint. No peer-reviewed full report was among the sources read.",
   "entry": "zadavotide-guraxetan",
   "sources": {
    "curium": {
     "kind": "sponsor",
     "label": "Curium: ECLIPSE trial met its primary endpoint (November 13, 2024)",
     "url": "https://www.curiumpharma.com/2024/11/13/eclipse-tiral-psma-prostate-cancer/",
     "date": "2024-11-13",
     "read": "2026-10-28"
    },
    "eclipse_reg": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT05204927 (177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer)",
     "url": "https://clinicaltrials.gov/study/NCT05204927",
     "nct": "NCT05204927",
     "read": "2026-10-28"
    }
   },
   "changed": null,
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "curium",
    "eclipse_reg"
   ],
   "class": "Beta-emitting PSMA radioligand"
  },
  {
   "id": "berobenatide",
   "name": "Berobenatide",
   "aliases": [
    "PF-08653944",
    "MET-097i",
    "MET097"
   ],
   "sponsor": "Pfizer; first developed by Metsera as MET-097i",
   "class": "Ultra-long-acting GLP-1 receptor agonist",
   "target": "GLP-1 receptor",
   "mechanism": "A long-lasting GLP-1 receptor agonist peptide that Pfizer describes as fully biased, given by injection weekly or, after a weekly start, monthly",
   "areas": [
    "obesity-diabetes"
   ],
   "indications": [
    "Obesity and overweight",
    "Obesity with type 2 diabetes",
    "Obstructive sleep apnoea with obesity",
    "Knee osteoarthritis with obesity"
   ],
   "phase": "phase 3",
   "phase_note": "Pfizer's pipeline update of November 3, 2026 lists it in phase 3 for chronic weight management; eleven phase 3 trials are registered, the newest (VESPER-OA 2, knee osteoarthritis) posted November 4, 2026",
   "phase_sources": [
    "pipe",
    "vesper4",
    "oa2"
   ],
   "ncts": [
    "NCT07311850",
    "NCT07400653",
    "NCT07595549",
    "NCT07792954",
    "NCT07794761",
    "NCT07794774",
    "NCT07823608",
    "NCT07845500",
    "NCT07874633",
    "NCT07881757",
    "NCT07915609"
   ],
   "last_readout": {
    "date": "2026-02-03",
    "result": "VESPER-3 phase 2b: up to 12.3% placebo-adjusted weight loss at 28 weeks after the switch from weekly to monthly dosing (10.5% counting everyone randomised); weight was still falling (company release)",
    "source": "p2b"
   },
   "next_milestone": {
    "what": "Primary completion of VESPER-4, the 3,578-person weekly phase 3 in overweight or obesity",
    "expected": "2027-09-21",
    "source": "vesper4"
   },
   "plain": "Berobenatide is a weight-loss injection that copies the gut hormone GLP-1, like semaglutide, but lasts long enough that Pfizer is testing it once a month. It is in large phase 3 trials and is not approved anywhere.",
   "scientific": "Berobenatide (PF-08653944, formerly Metsera's MET-097i) is a GLP-1 receptor agonist peptide built for an albumin-like half-life, which its developer calls fully biased. In the phase 2b VESPER-3 trial, Pfizer reports weight loss that kept going after people moved from weekly to monthly injections. The phase 3 VESPER programme tests weekly and monthly doses in obesity, type 2 diabetes, sleep apnoea and knee osteoarthritis, in Japan and China, and as a switch from weekly semaglutide or tirzepatide.",
   "entry": null,
   "sources": {
    "pipe": {
     "kind": "sponsor",
     "label": "Pfizer pipeline update, November 3, 2026 (berobenatide, phase 3, chronic weight management)",
     "url": "https://cdn.pfizer.com/pfizercom/product-pipeline/Q3%202026%20Pipeline%20Update_vfinal.pdf?VersionId=Ltaaulsg1IHmJvxHRLx.OXa.0v9KLY.4",
     "date": "2026-11-03",
     "read": "2026-11-04"
    },
    "p2b": {
     "kind": "sponsor",
     "label": "Pfizer: ultra-long-acting injectable GLP-1 RA, VESPER-3 phase 2b results (information as of February 3, 2026)",
     "url": "https://www.pfizer.com/news/press-release/press-release-detail/pfizers-ultra-long-acting-injectable-glp-1-ra-shows-robust",
     "date": "2026-02-03",
     "read": "2026-11-04"
    },
    "metsera": {
     "kind": "sponsor",
     "label": "Metsera: VESPER-1 phase 2b results for MET-097i, which it calls its foundational peptide (September 29, 2025)",
     "url": "https://www.biospace.com/press-releases/metsera-reports-positive-phase-2b-results-for-first-and-best-in-class-ultra-long-acting-glp-1-ra-candidate-met-097i-enabling-rapid-transition-into-phase-3",
     "date": "2025-09-29",
     "read": "2026-11-04"
    },
    "vesper4": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07311850 (VESPER-4)",
     "url": "https://clinicaltrials.gov/study/NCT07311850",
     "nct": "NCT07311850",
     "read": "2026-11-04"
    },
    "vesper5": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07400653 (VESPER-5, with type 2 diabetes)",
     "url": "https://clinicaltrials.gov/study/NCT07400653",
     "nct": "NCT07400653",
     "read": "2026-11-04"
    },
    "vesper6": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07595549 (VESPER-6, monthly)",
     "url": "https://clinicaltrials.gov/study/NCT07595549",
     "nct": "NCT07595549",
     "read": "2026-11-04"
    },
    "cnw": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07792954 (weekly, Chinese adults)",
     "url": "https://clinicaltrials.gov/study/NCT07792954",
     "nct": "NCT07792954",
     "read": "2026-11-04"
    },
    "jw": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07794761 (VESPER-JW, weekly, Japan)",
     "url": "https://clinicaltrials.gov/study/NCT07794761",
     "nct": "NCT07794761",
     "read": "2026-11-04"
    },
    "jm": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07794774 (VESPER-JM, monthly, Japan)",
     "url": "https://clinicaltrials.gov/study/NCT07794774",
     "nct": "NCT07794774",
     "read": "2026-11-04"
    },
    "osa1": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07823608 (VESPER-OSA 1)",
     "url": "https://clinicaltrials.gov/study/NCT07823608",
     "nct": "NCT07823608",
     "read": "2026-11-04"
    },
    "switch": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07845500 (VESPER-SWITCH)",
     "url": "https://clinicaltrials.gov/study/NCT07845500",
     "nct": "NCT07845500",
     "read": "2026-11-04"
    },
    "cnm": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07874633 (monthly, Chinese adults)",
     "url": "https://clinicaltrials.gov/study/NCT07874633",
     "nct": "NCT07874633",
     "read": "2026-11-04"
    },
    "osa2": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07881757 (VESPER-OSA 2)",
     "url": "https://clinicaltrials.gov/study/NCT07881757",
     "nct": "NCT07881757",
     "read": "2026-11-04"
    },
    "oa2": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07915609 (VESPER-OA 2, knee osteoarthritis)",
     "url": "https://clinicaltrials.gov/study/NCT07915609",
     "nct": "NCT07915609",
     "read": "2026-11-04"
    }
   },
   "changed": {
    "date": "2026-11-04",
    "what": "Added: Pfizer's phase 3 VESPER programme, newest trial posted November 4",
    "source": "oa2"
   },
   "last_checked": "2026-11-04",
   "explainer_sources": [
    "p2b",
    "metsera",
    "pipe",
    "switch"
   ]
  },
  {
   "id": "efinopegdutide",
   "name": "Efinopegdutide",
   "aliases": [
    "MK-6024",
    "HM12525A"
   ],
   "sponsor": "Merck (MSD)",
   "target": "GLP-1 and glucagon receptors",
   "mechanism": "Long-acting dual agonist aimed at liver fat",
   "areas": [
    "cardiometabolic",
    "gi"
   ],
   "indications": [
    "MASH",
    "Compensated MASH cirrhosis"
   ],
   "phase": "phase 2",
   "phase_note": "Phase 2b in MASH completed December 2025; no phase 3 registered when read",
   "phase_sources": [
    "p2b"
   ],
   "ncts": [
    "NCT05877547",
    "NCT06465186"
   ],
   "last_readout": {
    "date": "2025-12-29",
    "result": "Phase 2b in precirrhotic MASH reached primary completion; no results posted on the registry when read",
    "source": "p2b"
   },
   "next_milestone": {
    "what": "No phase 3 trial registered (registry search)",
    "expected": null,
    "source": "q"
   },
   "plain": "Efinopegdutide is a weekly injection being tested for fatty liver disease with inflammation. It copies two hormones that act on how the liver handles fat. Its main mid-stage trial has finished, and results are awaited.",
   "scientific": "Efinopegdutide (MK-6024) is a GLP-1 and glucagon receptor dual agonist. A 381-participant phase 2b trial in precirrhotic MASH reached primary completion in December 2025 and a trial in compensated cirrhosis in August 2026. No phase 3 trial was registered when the registry was read.",
   "entry": "efinopegdutide",
   "sources": {
    "p2b": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT05877547 (A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013))",
     "url": "https://clinicaltrials.gov/study/NCT05877547",
     "nct": "NCT05877547",
     "read": "2026-10-28"
    },
    "cirr": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06465186 (A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017))",
     "url": "https://clinicaltrials.gov/study/NCT06465186",
     "nct": "NCT06465186",
     "read": "2026-10-28"
    },
    "q": {
     "kind": "registry",
     "label": "ClinicalTrials.gov search for efinopegdutide (read October 28, 2026): no phase 3 study",
     "url": "https://clinicaltrials.gov/search?intr=efinopegdutide",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2025-12-29",
    "what": "Phase 2b reached primary completion",
    "source": "p2b"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "p2b",
    "cirr",
    "q"
   ],
   "class": "GLP-1 and glucagon receptor dual agonist"
  },
  {
   "id": "zelenectide-pevedotin",
   "name": "Zelenectide pevedotin",
   "aliases": [
    "BT8009"
   ],
   "sponsor": "Bicycle Therapeutics",
   "target": "Nectin-4",
   "mechanism": "A small constrained peptide that binds Nectin-4 on tumours and releases the toxin MMAE",
   "areas": [
    "oncology"
   ],
   "indications": [
    "Urothelial cancer",
    "Breast cancer",
    "Non-small-cell lung cancer with NECTIN4 amplification"
   ],
   "phase": "phase 2",
   "phase_note": "Duravelo-2 in urothelial cancer and further phase 2 trials",
   "phase_sources": [
    "dur2"
   ],
   "ncts": [
    "NCT06225596",
    "NCT06840483",
    "NCT06933329"
   ],
   "last_readout": null,
   "next_milestone": {
    "what": "Primary completion of Duravelo-2 (urothelial cancer)",
    "expected": "2028-03",
    "source": "dur2"
   },
   "plain": "Zelenectide pevedotin is a tiny ring-shaped peptide that finds a protein called Nectin-4 on some cancers and delivers a cell-killing drug to it. Because it is much smaller than an antibody, its makers hope it reaches into tumours better.",
   "scientific": "Zelenectide pevedotin (BT8009) is a bicyclic peptide that binds Nectin-4, conjugated to monomethyl auristatin E through a cleavable linker. It is designed to improve on Nectin-4 antibody-drug conjugates such as enfortumab vedotin, with better tumour penetration and less systemic toxicity, though a 2025 review questions the control arms of its trials. Duravelo-2 tests it in urothelial cancer.",
   "entry": "zelenectide-pevedotin",
   "sources": {
    "dur2": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06225596 (Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2))",
     "url": "https://clinicaltrials.gov/study/NCT06225596",
     "nct": "NCT06225596",
     "read": "2026-10-28"
    },
    "breast": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06840483 (Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer)",
     "url": "https://clinicaltrials.gov/study/NCT06840483",
     "nct": "NCT06840483",
     "read": "2026-10-28"
    },
    "lung": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06933329 (Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer)",
     "url": "https://clinicaltrials.gov/study/NCT06933329",
     "nct": "NCT06933329",
     "read": "2026-10-28"
    },
    "rev": {
     "kind": "paper",
     "label": "Cigliola A, et al. Zelenectide pevedotin (BT-8009): a bicyclic peptide toxin conjugate targeting nectin-4 for the treatment of bladder cancer. Expert Opin Investig Drugs 2025",
     "pmid": "40401457",
     "url": "https://pubmed.ncbi.nlm.nih.gov/40401457/",
     "read": "2026-10-28"
    },
    "bio": {
     "kind": "paper",
     "label": "Tweed JA, et al. The validation and clinical bioanalysis of the Bicycle Toxin Conjugate zelenectide pevedotin in human plasma. Bioanalysis 2025",
     "pmid": "39829185",
     "url": "https://pubmed.ncbi.nlm.nih.gov/39829185/",
     "read": "2026-10-28"
    }
   },
   "changed": null,
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "rev",
    "bio",
    "dur2"
   ],
   "class": "Bicyclic peptide-drug conjugate"
  },
  {
   "id": "lutetium-fap-2286",
   "name": "Lutetium Lu 177 FAP-2286",
   "aliases": [
    "177Lu-FAP-2286"
   ],
   "sponsor": "Novartis",
   "target": "Fibroblast activation protein (FAP)",
   "mechanism": "Delivers lutetium-177 to cancer-associated fibroblasts in tumour tissue",
   "areas": [
    "oncology"
   ],
   "indications": [
    "Advanced solid tumours"
   ],
   "phase": "phase 2",
   "phase_note": "LuMIERE, registered as phase 1/2",
   "phase_sources": [
    "lumiere"
   ],
   "ncts": [
    "NCT04939610"
   ],
   "last_readout": null,
   "next_milestone": {
    "what": "Primary completion of LuMIERE",
    "expected": "2027-12-31",
    "source": "lumiere"
   },
   "plain": "Many tumours are surrounded by support cells that display a protein called FAP. This radioactive drug homes in on FAP to irradiate the tumour from its surroundings. It is in early testing across several cancers.",
   "scientific": "FAP-2286 is a fibroblast activation protein-binding peptide used as a radioligand. LuMIERE is a phase 1/2 study of the lutetium-177 form in advanced solid tumours, with gallium-68 FAP-2286 imaging, examining safety, dosimetry and preliminary activity.",
   "entry": null,
   "sources": {
    "lumiere": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT04939610 (LuMIERE)",
     "url": "https://clinicaltrials.gov/study/NCT04939610",
     "nct": "NCT04939610",
     "read": "2026-10-28"
    }
   },
   "changed": null,
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "lumiere"
   ],
   "class": "Cyclic peptide radioligand"
  },
  {
   "id": "pl-5",
   "name": "PL-5",
   "aliases": [
    "antimicrobial peptide PL-5 spray"
   ],
   "sponsor": "Jiangsu ProteLight Pharmaceutical & Biotechnology",
   "target": "Bacterial membranes",
   "mechanism": "A topical spray of a membrane-active antimicrobial peptide",
   "areas": [
    "antimicrobial"
   ],
   "indications": [
    "Mild infections of diabetic foot ulcers"
   ],
   "phase": "phase 2",
   "phase_note": "Phase 2, placebo-controlled",
   "phase_sources": [
    "p2"
   ],
   "ncts": [
    "NCT06189638"
   ],
   "last_readout": null,
   "next_milestone": {
    "what": "Primary completion of the phase 2 diabetic foot ulcer trial",
    "expected": "2027-04-30",
    "source": "p2"
   },
   "plain": "PL-5 is a spray made from a peptide that kills bacteria. It is being tested on mildly infected foot ulcers in people with diabetes.",
   "scientific": "PL-5 is an antimicrobial peptide formulated as a topical spray, tested against placebo in a 90-patient phase 2 trial in mild diabetic foot ulcer infection. An earlier topical antimicrobial peptide, pexiganan, matched oral ofloxacin in one of two phase 3 trials in the same condition but never reached approval.",
   "entry": null,
   "sources": {
    "p2": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT06189638 (PL-5)",
     "url": "https://clinicaltrials.gov/study/NCT06189638",
     "nct": "NCT06189638",
     "read": "2026-10-28"
    },
    "pex": {
     "kind": "paper",
     "label": "Lipsky BA, et al. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized trial of pexiganan cream. Clin Infect Dis 2008",
     "pmid": "18990064",
     "url": "https://pubmed.ncbi.nlm.nih.gov/18990064/",
     "read": "2026-10-28"
    }
   },
   "changed": null,
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "p2",
    "pex"
   ],
   "class": "Antimicrobial peptide"
  },
  {
   "id": "pn-881",
   "name": "PN-881",
   "aliases": [],
   "sponsor": "Protagonist Therapeutics",
   "target": "IL-17A and IL-17F",
   "mechanism": "Blocks the IL-17 signals that drive psoriasis, taken by mouth",
   "areas": [
    "dermatology"
   ],
   "indications": [
    "Psoriasis (planned phase 2)",
    "Psoriatic arthritis, hidradenitis suppurativa, axial spondyloarthritis (planned)"
   ],
   "phase": "phase 1",
   "phase_note": "Phase 1 in healthy volunteers completed July 2026; the company plans a phase 2 psoriasis programme from early 2027",
   "phase_sources": [
    "p1",
    "ptgx",
    "q2"
   ],
   "ncts": [
    "NCT07153146"
   ],
   "last_readout": {
    "date": "2025-09-17",
    "result": "Preclinical data at EADV 2025: activity against all three IL-17 dimer forms (company release)",
    "source": "ptgx"
   },
   "next_milestone": {
    "what": "Start of a phase 2 psoriasis programme, on the strength of the phase 1 drug-level data, as the company expects",
    "expected": "2027-Q1",
    "source": "q2"
   },
   "plain": "PN-881 comes from the company behind icotrokinra and aims to block another psoriasis signal, IL-17, with a pill instead of an injection. It has finished its first safety study in healthy volunteers.",
   "scientific": "PN-881 is an oral peptide targeting the IL-17 pathway that binds IL-17A and IL-17F; preclinically it was active against all three IL-17 dimer forms, according to the company. A single- and multiple-ascending-dose phase 1 reached primary completion in July 2026, and a dose-ranging psoriasis trial is planned.",
   "entry": null,
   "sources": {
    "ptgx": {
     "kind": "sponsor",
     "label": "Protagonist Therapeutics: icotrokinra clinical data and PN-881 preclinical data at EADV 2025 (September 17, 2025)",
     "url": "https://www.biospace.com/press-releases/protagonist-announces-presentations-of-clinical-data-with-icotrokinra-in-plaque-psoriasis-and-preclinical-data-with-pn-881-at-the-eadv-2025-congress",
     "date": "2025-09-17",
     "read": "2026-10-28"
    },
    "p1": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT07153146 (Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects.)",
     "url": "https://clinicaltrials.gov/study/NCT07153146",
     "nct": "NCT07153146",
     "read": "2026-10-28"
    },
    "q2": {
     "kind": "sponsor",
     "label": "Protagonist: second quarter 2026 financial results and corporate update (August 5, 2026)",
     "url": "https://www.newswire.com/news/protagonist-reports-second-quarter-2026-financial-results-and-provides",
     "date": "2026-08-05",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-07-29",
    "what": "Phase 1 reached primary completion",
    "source": "p1"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "ptgx",
    "p1"
   ],
   "class": "Oral peptide antagonist"
  },
  {
   "id": "zosurabalpin",
   "name": "Zosurabalpin",
   "aliases": [
    "RG6006",
    "RO7223280"
   ],
   "sponsor": "Roche",
   "target": "LptB2FGC lipopolysaccharide transporter",
   "mechanism": "Traps lipopolysaccharide inside the bacterium so it cannot build its outer membrane",
   "areas": [
    "antimicrobial"
   ],
   "indications": [
    "Carbapenem-resistant Acinetobacter baumannii infections"
   ],
   "phase": "phase 1",
   "phase_note": "Phase 1 studies in healthy volunteers and critically ill patients completed; no later-phase trial registered when read",
   "phase_sources": [
    "p1a",
    "p1b"
   ],
   "ncts": [
    "NCT04605718",
    "NCT05614895"
   ],
   "last_readout": {
    "date": "2024-01-03",
    "result": "Nature 2024: a new antibiotic class that blocks lipopolysaccharide transport and treated drug-resistant A. baumannii in mice",
    "source": "nature"
   },
   "next_milestone": {
    "what": "No later-phase trial registered (registry search)",
    "expected": null,
    "source": "q"
   },
   "plain": "Some hospital germs, like carbapenem-resistant Acinetobacter, resist almost every antibiotic. Zosurabalpin is a ring-shaped peptide antibiotic that stops these bacteria from building their outer shell. It worked in mice and has been tested for safety in people.",
   "scientific": "Zosurabalpin is a tethered macrocyclic peptide that inhibits the LptB2FGC complex and blocks transport of lipopolysaccharide to the outer membrane of Acinetobacter baumannii. Its discoverers note that no new antibiotic class active against A. baumannii had reached patients in over 50 years. Two phase 1 studies are complete, and 2026 laboratory surveys report activity against global carbapenem-resistant isolates.",
   "entry": null,
   "sources": {
    "nature": {
     "kind": "paper",
     "label": "Zampaloni C, et al. A novel antibiotic class targeting the lipopolysaccharide transporter. Nature 2024;625:566-571",
     "pmid": "38172634",
     "url": "https://pubmed.ncbi.nlm.nih.gov/38172634/",
     "read": "2026-10-28"
    },
    "p1a": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT04605718 (A Study To Investigate The Safety, Tolerability And Pharmacokinetics (PK) Of RO7223280 Following Intravenous Administration In Healthy Participants)",
     "url": "https://clinicaltrials.gov/study/NCT04605718",
     "nct": "NCT04605718",
     "read": "2026-10-28"
    },
    "p1b": {
     "kind": "registry",
     "label": "ClinicalTrials.gov NCT05614895 (A Study to Investigate the Pharmacokinetics of RO7223280 in Critically Ill Participants With Bacterial Infections)",
     "url": "https://clinicaltrials.gov/study/NCT05614895",
     "nct": "NCT05614895",
     "read": "2026-10-28"
    },
    "surv": {
     "kind": "paper",
     "label": "Mancini S, et al. In vitro activity of zosurabalpin against a global set of carbapenem-resistant Acinetobacter baumannii clinical isolates. Antimicrob Agents Chemother 2026",
     "pmid": "42747471",
     "url": "https://pubmed.ncbi.nlm.nih.gov/42747471/",
     "read": "2026-10-28"
    },
    "q": {
     "kind": "registry",
     "label": "ClinicalTrials.gov search for zosurabalpin, RG6006 and RO7223280 (read October 28, 2026): two phase 1 studies, no later phase",
     "url": "https://clinicaltrials.gov/search?intr=zosurabalpin%20OR%20RG6006%20OR%20RO7223280",
     "read": "2026-10-28"
    }
   },
   "changed": null,
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "nature",
    "p1a",
    "p1b",
    "surv"
   ],
   "class": "Tethered macrocyclic peptide antibiotic"
  },
  {
   "id": "glp1-gip-lanifibranor",
   "name": "GLP-1-GIP-lanifibranor conjugate",
   "aliases": [
    "quintuple agonist"
   ],
   "sponsor": "Academic research (published in Nature)",
   "target": "GLP-1 and GIP receptors plus PPAR-alpha, -gamma and -delta",
   "mechanism": "A GLP-1/GIP co-agonist peptide that carries the pan-PPAR drug lanifibranor into target cells",
   "areas": [
    "obesity-diabetes"
   ],
   "indications": [
    "Obesity and diabetes (mouse studies only)"
   ],
   "phase": "preclinical",
   "phase_note": "Announced in a peer-reviewed paper; mouse data only, no human trial registered",
   "phase_sources": [
    "nature"
   ],
   "ncts": [],
   "last_readout": {
    "date": "2026-04-29",
    "result": "In obese mice it lowered body weight, food intake and blood glucose more than GLP-1/GIP co-agonism or semaglutide",
    "source": "nature"
   },
   "next_milestone": {
    "what": "No human trial announced",
    "expected": null,
    "source": "nature"
   },
   "plain": "Scientists built one molecule that hits five targets: two gut-hormone receptors on the cell surface and three fat-and-sugar switches inside the cell. In mice it beat semaglutide. It has never been given to a person.",
   "scientific": "The conjugate links a GLP-1R/GIPR co-agonist peptide to lanifibranor, a pan-PPAR agonist. In obese, insulin-resistant mice it lowered body weight, food intake and blood glucose more than GLP-1R/GIPR co-agonism or semaglutide, and its effects were blunted when GLP-1R, GIPR or PPAR-delta was inhibited. It is a mouse-stage finding.",
   "entry": null,
   "sources": {
    "nature": {
     "kind": "paper",
     "label": "Liskiewicz D, et al. GLP-1R-GIPR-PPARalpha/gamma/delta quintuple agonism corrects obesity and diabetes in mice. Nature 2026;653:776-785",
     "pmid": "42056522",
     "url": "https://pubmed.ncbi.nlm.nih.gov/42056522/",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-04-29",
    "what": "Published in Nature (preclinical)",
    "source": "nature"
   },
   "last_checked": "2026-10-28",
   "explainer_sources": [
    "nature"
   ],
   "class": "Peptide-small-molecule conjugate"
  },
  {
   "id": "asc37",
   "name": "ASC37",
   "aliases": [
    "ASC37o",
    "ASC37i"
   ],
   "sponsor": "Ascletis Pharma",
   "class": "Triple-agonist peptide (oral tablet and long-acting injection)",
   "target": "GLP-1, GIP and glucagon receptors",
   "mechanism": "Activates all three receptors at once; designed for once-weekly dosing by mouth",
   "areas": [
    "obesity-diabetes"
   ],
   "indications": [
    "Obesity (planned)"
   ],
   "phase": "announced",
   "phase_note": "Announced by Ascletis on October 19, 2026 with monkey data; the company expects to submit an FDA investigational new drug application for the ASC37o tablet in the fourth quarter of 2026, and for tablets that pair ASC37 with its amylin agonist ASC36. No ASC37 trial is registered on ClinicalTrials.gov",
   "phase_sources": [
    "rel",
    "q"
   ],
   "ncts": [],
   "last_readout": {
    "date": "2026-10-19",
    "result": "Company-reported monkey data: ASC37o tablets reached a half-life of up to about 79 hours (about 3.3 days) and oral bioavailability of 3.5% to 7.9% at steady state",
    "source": "rel"
   },
   "next_milestone": {
    "what": "FDA investigational new drug submission for the ASC37o tablet, as the company expects",
    "expected": "2026-Q4",
    "source": "rel"
   },
   "plain": "ASC37 is a lab-made peptide from Ascletis meant to act on three appetite and blood-sugar hormone receptors at once, taken as a tablet once a week. So far it has been tested only in animals, and the company has not yet asked to start human trials.",
   "scientific": "Ascletis describes ASC37 as a GLP-1R/GIPR/GCGR triple peptide agonist, made as a once-weekly oral tablet (ASC37o) and as a once-monthly to once-quarterly subcutaneous injection (ASC37i). In non-human primates at steady state, ASC37o reached a half-life of up to 79 hours and oral bioavailability of 3.5% to 7.9%, according to the company. The company also plans a fixed-dose tablet of ASC37 with its amylin receptor agonist ASC36. These are company-reported pre-clinical figures, not peer-reviewed results.",
   "explainer_sources": [
    "rel"
   ],
   "entry": null,
   "sources": {
    "rel": {
     "kind": "sponsor",
     "label": "Ascletis: positive preclinical data for its once-weekly oral peptide pipeline for obesity (October 19, 2026)",
     "url": "https://www.prnewswire.com/news-releases/ascletis-announces-positive-preclinical-data-for-the-most-comprehensive-once-weekly-oral-peptide-pipeline-for-the-treatment-of-obesity-302912813.html",
     "date": "2026-10-19",
     "read": "2026-10-28"
    },
    "q": {
     "kind": "registry",
     "label": "ClinicalTrials.gov search for ASC37 (read October 28, 2026): no study found",
     "url": "https://clinicaltrials.gov/search?intr=ASC37",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-10-19",
    "what": "Ascletis announced ASC37's monkey data and an IND expected in the fourth quarter of 2026",
    "source": "rel"
   },
   "last_checked": "2026-10-28"
  },
  {
   "id": "pn-477",
   "name": "PN-477",
   "aliases": [
    "PN-477o",
    "PN-477sc"
   ],
   "sponsor": "Protagonist Therapeutics",
   "class": "Triple-agonist peptide (oral and injectable)",
   "target": "GLP-1, GIP and glucagon receptors",
   "mechanism": "Activates all three receptors; engineered to stay stable when swallowed",
   "areas": [
    "obesity-diabetes"
   ],
   "indications": [
    "Obesity"
   ],
   "phase": "announced",
   "phase_note": "Announced by Protagonist as a development candidate in June 2025. On August 5, 2026 the company said a phase 1 study of the injectable form had begun and a phase 1 of the oral form is expected in the first half of 2027. No PN-477 study is registered on ClinicalTrials.gov",
   "phase_sources": [
    "q2",
    "q"
   ],
   "ncts": [],
   "last_readout": {
    "date": "2025-06-30",
    "result": "Development candidate nominated; the company described pre-clinical effects on obesity and blood sugar in mice, dogs and monkeys without publishing figures",
    "source": "nom"
   },
   "next_milestone": {
    "what": "Start of a phase 1 study of oral PN-477, as the company expects",
    "expected": "2027-H1",
    "source": "q2"
   },
   "plain": "PN-477 is a peptide from Protagonist, the company behind the psoriasis pill icotrokinra, built to act on three gut-hormone receptors that control appetite and blood sugar. The company says a first human study of the injected version has started and a pill version will follow, but no trial record is public on ClinicalTrials.gov yet.",
   "scientific": "Protagonist nominated PN-477 in June 2025 as a GLP-1R/GIPR/GCGR triple agonist peptide engineered to be orally stable, for once-daily oral (PN-477o) and once-weekly subcutaneous (PN-477sc) use. The company reported in vitro activity at all three receptors and pre-clinical work in diet-induced obese mice, normal dogs and cynomolgus monkeys, describing effects on obesity and glycaemic control without figures. In August 2026 it said a phase 1 study of PN-477sc had begun.",
   "explainer_sources": [
    "nom",
    "q2"
   ],
   "entry": null,
   "sources": {
    "nom": {
     "kind": "sponsor",
     "label": "Protagonist: nomination of PN-477, an oral and injectable GLP-1R, GIPR and GCGR triple agonist peptide development candidate for obesity (June 30, 2025)",
     "url": "https://www.newswire.com/news/protagonist-announces-nomination-of-pn-477-an-oral-and-injectable-glp-1r-gipr",
     "date": "2025-06-30",
     "read": "2026-10-28"
    },
    "q2": {
     "kind": "sponsor",
     "label": "Protagonist: second quarter 2026 financial results and corporate update (August 5, 2026)",
     "url": "https://www.newswire.com/news/protagonist-reports-second-quarter-2026-financial-results-and-provides",
     "date": "2026-08-05",
     "read": "2026-10-28"
    },
    "q": {
     "kind": "registry",
     "label": "ClinicalTrials.gov search for PN-477 and for Protagonist studies started since June 2025 (read October 28, 2026): no PN-477 study found",
     "url": "https://clinicaltrials.gov/search?intr=PN-477",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-08-05",
    "what": "Protagonist said a phase 1 study of injectable PN-477 had begun",
    "source": "q2"
   },
   "last_checked": "2026-10-28"
  },
  {
   "id": "oral-la-pth",
   "name": "Oral long-acting PTH analog (LA-PTH)",
   "aliases": [
    "oral LA-PTH"
   ],
   "sponsor": "OPKO Health and Entera Bio",
   "class": "Oral parathyroid hormone analog peptide",
   "target": "Parathyroid hormone receptor",
   "mechanism": "A long-acting PTH variant from OPKO in Entera's N-Tab oral tablet, meant to replace missing parathyroid hormone",
   "areas": [
    "endocrine",
    "rare-disease"
   ],
   "indications": [
    "Hypoparathyroidism (planned)"
   ],
   "phase": "announced",
   "phase_note": "Announced by OPKO Health and Entera Bio on February 4, 2026, in a release Entera filed with the SEC: pre-clinical, with an FDA investigational new drug application expected in late 2026. No study of the long-acting analog is registered on ClinicalTrials.gov",
   "phase_sources": [
    "filing",
    "q"
   ],
   "ncts": [],
   "last_readout": {
    "date": "2025-12",
    "result": "Pre-clinical pharmacokinetic and pharmacodynamic data the companies call favourable, reported without figures",
    "source": "filing"
   },
   "next_milestone": {
    "what": "FDA investigational new drug application, as the companies expect",
    "expected": "2026-Q4",
    "source": "filing"
   },
   "plain": "OPKO and Entera are developing a once-a-day tablet of a long-acting form of parathyroid hormone, for people whose bodies make too little of it. It has been studied only in animals so far, and the companies plan to ask FDA to start human trials in late 2026.",
   "scientific": "The programme pairs OPKO's long-acting PTH variants with Entera's N-Tab oral peptide delivery platform, aiming at a once-daily tablet for hypoparathyroidism. The companies say their pre-clinical data support a single once-daily tablet at a significantly lower daily dose, without publishing figures.",
   "explainer_sources": [
    "filing"
   ],
   "entry": null,
   "sources": {
    "filing": {
     "kind": "filing",
     "label": "Entera Bio Form 8-K, exhibit 99.1: OPKO Health and Entera Bio expand partnership to advance an oral long-acting PTH tablet for hypoparathyroidism (February 4, 2026)",
     "url": "https://www.sec.gov/Archives/edgar/data/1638097/000117891326000300/exhibit_99-1.htm",
     "date": "2026-02-04",
     "read": "2026-10-28"
    },
    "q": {
     "kind": "registry",
     "label": "ClinicalTrials.gov search for hypoparathyroidism studies sponsored by Entera or OPKO (read October 28, 2026): only the earlier oral PTH(1-34) studies, none of the long-acting analog",
     "url": "https://clinicaltrials.gov/search?cond=hypoparathyroidism&spons=Entera%20OR%20OPKO",
     "read": "2026-10-28"
    }
   },
   "changed": {
    "date": "2026-02-04",
    "what": "The companies accelerated development and set an IND for late 2026",
    "source": "filing"
   },
   "last_checked": "2026-10-28"
  }
 ],
 "searches": {
  "announced": {
   "date": "2026-10-28",
   "where": "Company releases and SEC filings (Ascletis, Protagonist, Viking, Zealand, Pfizer with the former Metsera molecules, Novo Nordisk, Hengrui, Innovent, Boehringer Ingelheim with Gubra, Structure, Rivus, Onconic, OPKO and Entera), ObesityWeek 2026, EASD 2026 and AASLD announcements, licensing-deal news, and Reuters, Endpoints, Fierce Biotech, STAT and Bloomberg coverage; every candidate was then looked up on ClinicalTrials.gov.",
   "result": "Three peptides met the bar: made public by their developer, with no trial record on ClinicalTrials.gov.",
   "none": "No peptide met the bar.",
   "excluded": "Left out: candidates the companies describe as small molecules (Rivus's RV-8451, Ascletis's ASC39 and the oral molecules Zealand licensed from OTR Therapeutics); candidates whose company does not say whether they are peptides (Hengrui's HRS-1596, licensed to Novo Nordisk, and Onconic's OCN-501); and announced peptides that already have registered trials (Boehringer Ingelheim's BI 3034701, Gubra's GUB-UCN2 and Ascletis's ASC35 and ASC36), which belong in a clinical phase rather than here."
  },
  "rumoured": {
   "date": "2026-10-28",
   "where": "Reuters, Endpoints News, Fierce Biotech, STAT and Bloomberg, for peptide molecules reported but not confirmed by their developers.",
   "result": "Rows that met the bar are listed below, each with its outlet and date.",
   "none": "None met the bar. Every report found either rested on a company's own announcement (those molecules are listed under their phase above) or did not name a specific peptide molecule."
  }
 }
}
